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ABSTRACT 
 
Background                                                                                                                      
HIV is a risk factor for empyema. HIV-infected patients with empyema appear to have worse 
outcomes.  This study assessed whether HIV infection affected aetiology or outcomes of 
patients with empyema.   
Methods                                                                                                                                      
A retrospective study of patients with empyema admitted to CHBAH from January 2006 to 
December 2009 was conducted.  HIV-infected and non-infected patients were evaluated for 
differences in aetiology and outcomes.  Sub-analysis according to CD4 counts and 
antiretroviral use in HIV-infected patients was performed. 
Results                                                                                                                                      
0f 172 patients, 125 (73%) were HIV-infected.  HIV infected patients with lower CD4 counts 
were more often diagnosed with clinical tuberculosis (p<0.05).  Aetiology of empyema was 
frequently not determined in HIV non-infected patients (p<0.05).  More patients on 
antiretrovirals underwent thoracic surgery (p<0.05) and had shorter hospital stays than those 
not on antiretrovirals (p<0.05). 
Conclusions                                                                                                                              
No differences in empyema aetiology among HIV-infected versus non-infected patients were 
found.  Antiretroviral use was associated with improved outcomes.  
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INTRODUCTION 
 
Empyema thoracis; the presence of pus in the pleural space,
1, 2, 3 
remains a problem in 
developing countries,
4
 its course is often prolonged and frequently requires surgical drainage.  
HIV infection is a risk factor for empyema
1
 and complicates pneumonia more frequently in 
HIV infected patients.
5
   Reported risk factors for the development of empyema include 
serum albumin <30 g/dl, intravenous drug use, ethanol abuse, younger age, male sex and 
current smoking. 
6 
In our experience, the majority of patients with empyema are HIV infected and present with 
late stages of empyema.  Despite expected low success rates of closed tube thoracostomy in 
the treatment of late empyema
7
 it remains first-line therapy at our hospital as cardiothoracic 
services are limited and many patients are critically ill and unable to tolerate aggressive 
surgical procedures.   
There is an impression that HIV infected patients do worse clinically.  Limited literature 
exists to support this, some reports claim patients with CD4 counts <200 cells/mm
3 
have 
higher complication rates and a poorer prognosis.
5
 
This study compares microbiological aetiology, outcomes including; length of stay, whether 
surgical intervention was offered and local complications of tube thoracostomy, in patients 
with empyema according to HIV status.  A secondary objective is to compare aetiology and 
outcomes in patients with HIV infection stratified according to CD4 cell count (≥200 
cells/mm
3
 or <200 cells/mm
3
) and antiretroviral usage. 
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METHODS 
 
CHBAH is a large academic hospital in Soweto Johannesburg, with 847 medical beds.  It is 
the only in-patient facility for the greater Soweto area and serves as a referral centre for 
Southern Gauteng and the North West Province. The CHBAH Respiratory Unit database 
from January 2006 to December 2009 was reviewed.  An Excel (Microsoft Corporation, 
Bellevue, WA) database was compiled from discharge summaries and case notes of patients 
referred to the Respiratory Unit.   Permission to use the database was obtained from the 
database manager and permission to conduct this review was obtained by the Human 
Research Ethics committee of the University of the Witwatersrand. 
Patients meeting at least one of the established criteria of empyema; a) aspiration of pus from 
the pleural space, b) pleural fluid pH <7.2 or pleural fluid glucose <3.4 mmol/l, or c) positive 
microbial stain and/or culture, 
1, 2 
were included.   
Patients were divided into aetiological groups based upon initial pleural fluid results: [1] 
proven tuberculosis (TB), [2] clinical TB, [3] dual (TB and bacterial infection), [4] bacterial, 
[5] non-tuberculous mycobacteria (NTM) and [5] unknown.  For proven TB either pleural 
fluid or sputum samples demonstrated Acid-Fast Bacilli (AFB) on microscopy and/or 
cultured Mycobacterium tuberculosis, or pleural biopsy demonstrated histological features of 
tuberculous infection.  Patients with radiological features of TB, those in whom clinical 
suspicion of TB existed or responded to a trial of anti-tuberculous therapy were classified as 
clinical TB.  Patients diagnosed with proven TB who also cultured a bacterial organism in 
their pleural fluid were classified as dual.  Patients with bacterial infections were subdivided 
into Gram-positive, Gram-negative and polymicrobial infections.  Patients in whom pleural 
3 
 
fluid analysis or histology failed to identify a microbiological aetiology were classified as 
unknown. 
Outcomes were defined as: [1] resolution of empyema via closed tube thoracostomy in ≤14 
days, [2] resolution of empyema via closed tube thoracostomy but requiring insertion of 
multiple tubes or prolonged drainage (>14 days), [3] long-term open tube thoracostomy, [4]  
cardiothoracic intervention and [5] death.  Length of stay was compared among each group. 
Complications were defined as:  [1] wound sepsis at tube thoracostomy site and [2] secondary 
infection of the pleural space. 
Statistical analysis was performed using STATA 10 software (StataCorp LP, College Station, 
Texas).  Univariate analyses were performed in each of the groups against known risk factors 
for empyema; age, smoking, ethanol abuse and male sex.   Association between categorical 
variables were tested using Fisher’s exact test, odds ratios and 95% confidence intervals were 
calculated.  Continuous variables with parametric distributions were tested with the student’s 
t-test, those with nonparametric distributions with the Wilcoxon Rank Sum test.  Where 
significance of risk factors was found between groups on univariate analysis, they were 
further analysed using multivariate regression.  Significance was considered as a P value of 
<0.05. 
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250 Records Reviewed 
RESULTS 
 
Two hundred and fifty records were reviewed, 78 patients were excluded (fig 3.1).  The 29 
patients excluded for chronic/unresolved empyema were patients that had been previously 
admitted for primary empyema, prior to the start date of the study, and had returned with 
complications during the study period.  We felt that inclusion of these patients would create 
bias.        
Figure 3.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Flowchart summarising patient inclusion. 
125 HIV Infected 
47 HIV non-infected 172 Patients included 
78 Patients Excluded:                                 
- 29 Unresolved / Chronic empyema                            
- 19 Insufficient Data                                                                          
 - 7 HIV status unknown                                          
 - 12 No smoking or ethanol history 
- 13 Iatrogenic empyema                                         
- 8 Sub-diaphragmatic pathology                    
- 3 Malignant effusions                                   
- 2 Penetrating chest trauma                           
- 1 Not biochemically empyema                     
- 1 Post thoracic surgery                                      
- 2 Chest wall abscess, not empyema 
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In total 172 patients were included, mean age was 39 (14-78).  The study group comprised 
110 (64%) males.  Using all cause admissions to the medical wards during the study period, it 
was found that males were at greater risk of developing empyema (p <0.05, OR 2.40, 95% CI 
2.00-2.88).  HIV infection was present in 125 (73%) patients with empyema.  Amongst the 
HIV infected group, median CD4 count was 128 cells/mm
3 
(1-885 cells/mm
3
, IQR 62-219 
cells/mm
3
), 88 (70.4%) had a CD4 count <200 cells/mm
3 
and 19 (15.2%) were on 
antiretroviral therapy (fig 3.2). 
Figure 3.2 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Flowchart summarising HIV infected patients’ characteristics 
 
 
With regards the reported risk factors for the development of empyema, statistical differences 
were found among the HIV infected and non-infected groups for age (p <0.05), with 
125 HIV Infected  
 
88 CD4 count <200 cells/mm3 
 
37 CD4 count ≥ 200 cells/mm3 
 
14 on ART 
(11.2%) 
5 on ART 
(4%) 
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empyema occurring amongst younger patients with HIV, and sex  (p <0.05), with HIV 
infected males having a greater risk of developing empyema.  In HIV infected patients 
stratified according to CD4 cell count,
 
ethanol abuse was found to be a significant risk factor 
in the group with CD4 cell counts ≥ 200 cells/mm3 (p <0.05).  No differences in risk factors 
were found in HIV infected patients stratified according to antiretroviral usage.  
Microbiological aetiologies were as follows; 34 (19.8%) patients had proven TB, 34 (19.8%) 
had clinical TB, 8 (4.7%) had dual infections, 55 (32%) had bacterial infections, 1 (0.6%) had 
NTM infection, and in 40 (23.3%), no microbiological aetiology was identified.  One patient 
cultured both Streptococcus pneumoniae and NTM and was classified as bacterial. We report 
5 cases of Salmonella non-typhi empyema, all five patients were HIV infected; four had CD4 
counts <100 cells/mm
3
, the fifth was on antiretroviral therapy with a CD4 count of 118 
cells/mm
3
.  Pleural fluid cultured Salmonella spp. in all five, in one Salmonella spp. was also 
cultured on sputum (Table 3.1). 
With regards aetiology; HIV non-infected patients more often had no identifiable 
microbiological aetiology identified (p <0.05, OR 0.18, CI 0.08-0.40) whereas HIV infected 
patients with lower CD4 cell counts had a significantly greater likelihood of being diagnosed 
with clinical TB (p <0.05, OR 2.98, CI 1.22-7.3) and showed a trend towards having a greater 
incidence of infections caused by Gram-negative organisms (OR 10.6).  Antiretroviral 
therapy did not alter the aetiology of empyema in this series (Table 3.2).      
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Table 3.1 
 
Microbiological aetiologies by HIV Status 
 
 HIV Positive (n=125) HIV Negative (n=47) 
   
* Proven Tuberculosis:  34 (27.2%) 8 (17%) 
 Pleural Fluid Microscopy AFB positive 7 (20.6%) 0 
 Pleural Fluid culture MTB positive  18 (53.0%) 1 (12.5%) 
 Sputum Microscopy AFB positive 12 (35.5%) 4 (50%) 
 Sputum Culture MTB positive 9 (26.5%) 2 (25%) 
Blood Culture MTB positive  3 (8.8%) 0 
 Pleural Biopsy consistent with tuberculosis 2 (5.9%) 2 (25%) 
   
Clinical Tuberculosis: 27 (21.6%) 7 (14.9%) 
   
* Bacterial Infection: 53 (42.4%) 10 (21.3%) 
 S. pneumoniae 22 (41.5%) 3 (30%) 
S. anginosus (formerly S. milleri) 5 (9.4%) 5 (50%) 
K. pneumonia 5 (9.4%) 1 (10%) 
 Salmonella spp. 5 (9.4%) 0 
S. aureus 3 (5.7%) 0 
Peptostreptococcus spp. 3 (5.7%) 1 (10%) 
 E. coli 3 (5.7%) 0 
Prevotella spp. 2 (3.8%) 3 (30%) 
Nocardia spp. 2 (3.8%) 0 
H. influenza 2 (3.8%) 0 
P. mirabilis 2 (3.8%) 0 
 P. aeruginosa 2 (3.8%) 0 
E. faecium 1 (1.9%) 0 
 E. faecalis 1 (1.9%) 0 
 S. viridans 1 (1.9%) 0 
S. pyogenes 1 (1.9%) 0 
A. baumannii 1 (1.9%) 0 
 Streptococcus Group F 1 (1.9%) 0 
Streptococcus Group C 0 1 (10%) 
   
Non-tuberculous mycobacteria: 1 (0.8%) 0 
 Mycobacterium avium-intracellulare complex 1 (0.8%) 0 
   
Unknown: 18 (14.4%) 22 (46.8%) 
   
MTB = Mycobacterium tuberculosis 
* Includes those with dual infection. 
Proof of MTB often obtained by more than one method. 
Polymicrobial infection in 13 patients.
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Table 3.2 
 
Differences in aetiology of empyema 
 
   P OR (95% CI) 
     
† HIV infected versus non infected patients: HIV Negative (n=47) HIV Positive (n=125)   
 Proven tuberculosis 8 34 >0.05 1.29 (0.52 – 3.2) 
 Clinical tuberculosis 7 27 >0.05 1.71 (0.65 – 4.45) 
 Dual Infection 0 8 * * 
 Bacterial Infection 10 45 >0.05 2.10 (0.91 – 4.82) 
 - Gram-positive 5  31 >0.05 0.94 (0.21 – 4.30) 
 - Gram-negative 1 13 >0.05 10.60 (0.72 – 156.07) 
 - Polymicrobial 4 9 >0.05 0.25 (0.51 – 1.27) 
 Non-tuberculous mycobacteria 0 1 * * 
 Unknown aetiology 22 18 <0.05 0.18 (0.08 – 0.40) 
     
‡ CD4 <200 versus ≥200 cells/mm3: CD4 < 200 (n=88) CD4 ≥ 200 (n=37)   
 Proven tuberculosis 26 8 >0.05 0.36 (0.11 – 1.37) 
 Clinical tuberculosis 14 13 <0.05 2.98 (1.22 – 7.30) 
 Dual Infection 4 4 >0.05 2.33 (0.54 – 10.07) 
 Bacterial Infection 36 9 >0.05 0.46 (0.19 – 1.09) 
 Non-tuberculous mycobacteria 1 0 * * 
 Unknown aetiology 11 7 >0.05 1.75 (0.61 – 5.00) 
     
¤ ART versus no ART: ART (n=19) No ART (n=106)   
 Proven tuberculosis 6 28 >0.05 1.29 (0.36 – 4.06) 
 Clinical tuberculosis 7 20 >0.05 2.51 (0.73 – 7.94) 
 Dual Infection 0 8 * * 
 Bacterial Infection 3 42 >0.05 0.29 (0.05 – 1.10) 
 Non-tuberculous mycobacteria 0 1 * * 
 Unknown aetiology 3 15 >0.05 1.14 (0.19 – 4.72) 
     
ART = Antiretroviral therapy 
* P value, odds ratios and 95% confidence intervals were not calculated in groups which included a zero. 
† Adjusted in logistic regression analysis for age and sex. 
‡ Adjusted in logistic regression analysis for ethanol abuse. 
¤ Univariate analysis using 2-tailed Fisher’s exact test. 
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Tube thoracostomas were inserted in the general medical wards in all but 11 (6.4%) patients; 6 
(3.5%) were transferred to cardiothoracic surgeons as their pleural collections were not amenable 
to tube thoracostomy, 3 (1.8%) had very small collections which were treated medically and 2 
(1.2%) refused further hospital treatment.   
Following closed tube thoracostomy; 16 (10%) patients had complete resolution of empyema 
within 14 days, 34 (20.4%) had resolution with prolonged drainage or multiple tubes.  Following 
14 days of closed tube thoracostomy, 47 (28.1%) were discharged home with an open tube 
thoracostoma; 14 (29.8%) of these following basal tube insertion by cardiothoracic surgeons.  
Thirty eight (22.8%) patients underwent cardiothoracic surgery; 35 had pleural toilette and basal 
tube insertion with subsequent resolution, 1 had a decortication, and 2 required surgical 
thoracostomy.  Prior to resolution of empyema a further 12 (7%) patients refused further 
treatment and discharged themselves from hospital.   
Of the patients converted to open tube thoracostomy; 6 (12.8%) were followed up by 
cardiothoracic services, 11 (23.4%) had resolution of empyema, 23 (48.9%) defaulted follow up, 
5 (10.6%) were transferred to cardiothoracic surgeons for a procedure; toilette, decortication, 
thoracostomy or thoracoplasty and 2 (4.3%) demised due to ongoing pleural sepsis.  
Overall length of stay was a median of 29 days (3-118 days).  No differences were found with 
regards to length of stay between HIV infected and non-infected patients or between those 
stratified according to CD4 cell count.  Patients on antiretroviral therapy had significantly shorter 
lengths of stay than those not on antiretroviral therapy. 
Patients were evaluated for development of complications; 4 (2.4%) developed wound sepsis at 
tube thoracostomy site and 26 (15.6%) developed secondary infection of their pleural space.  
Mortality in this series was 12.8% (22/172), 20 patients died in the medical wards and 2 died 
post surgical intervention.  
10 
 
Regarding outcomes and complications; HIV infected patients on antiretrovirals are more likely 
to be offered cardiothoracic intervention (p <0.05, OR3.43, CI 1.03-10.90).  Length of stay was 
shorter (p <0.05) and, though not statistically significant, there were no mortalities amongst 
patients on antiretroviral therapy.  No other differences were found between the various groups 
(Table 3.3). 
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Table 3.3 
 
Differences in outcomes and complications of empyema 
 
   P OR (95%) 
     
† HIV infected versus non infected patients: HIV Negative (n=47) HIV Positive (n=125)   
 § Length of stay  27 (4 – 94) 29 (3 – 118) >0.05  
 Resolution Simple 4 12 >0.05 0.83 (0.24 – 2.88) 
 Resolution Complicated 8 26 >0.05 1.38 (0.54 – 3.52) 
 Long term open tube thoracostomy 13 32 >0.05 0.90 (0.41 – 1.99) 
 Surgical intervention  12 26 >0.05 1.13 (0.31 – 1.62) 
 Death 6 16 >0.05 0.78 (0.40 – 3.40) 
 Wound sepsis at tube thoracostomy site 1 3 >0.05 1.21 (0.10 – 14.72) 
 Secondary infection of pleural space 5 21 >0.05 2.19 (0.71 – 6.71) 
     
‡ CD4 <200 versus ≥200 cells/mm3: CD4 < 200 (n=88) CD4 ≥ 200 (n=37)   
 § Length of stay  29 (4 – 118) 31 (3 – 88) >0.05  
 Resolution Simple 8 4 >0.05 1.14 (0.32 – 4.09) 
 Resolution Complicated 18 8 >0.05 1.11 (0.43 – 2.90) 
 Long term open tube thoracostomy 23 9 >0.05 0.99 (0.40 – 2.45) 
 Surgical intervention  18 8 >0.05 1.07 (0.42 – 2.75) 
 Death 14 2 >0.05 0.27 (0.06 – 1.30) 
 Wound sepsis at tube thoracostomy site 3 0 * * 
 Secondary infection of pleural space 15 6 >0.05 1.00 (0.99 – 1.00) 
     
¤ ART versus no ART: ART (n=19) No ART (n=106)   
 § Length of stay  37 (19 – 71) 27 (3 – 118) <0.05  
 Resolution Simple 1 11 >0.05 0.47 (0.01 – 3.60) 
 Resolution Complicated 4 22 >0.05 0.98 (0.22 – 3.52) 
 Long term open tube thoracostomy 5 27 >0.05 1.01 (0.26 – 3.32) 
 Surgical intervention  8 18 <0.05 3.43 (1.03 – 10.90) 
 Death 0 16 * * 
 Wound sepsis at tube thoracostomy site 1 2 >0.05 2.89 (0.05 – 57.56) 
 Secondary infection of pleural space 2 19 >0.05 0.54 (0.06 – 2.61) 
       
ART = Antiretroviral therapy                     † Adjusted in logistic regression analysis for age and sex.             
‡ Adjusted in logistic regression analysis for ethanol abuse, CD4 cell count only done for HIV.              ¤ Univariate analysis using 2-tailed Fisher’s exact test                   
* P value, odds ratios and 95% confidence intervals were not calculated in groups which included a zero.              § Length of stay adjusted in linear regression analysis.
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 DISCUSSION 
 
Empyema thoracis remains an important problem in South Africa.  The majority of 
empyemas (>50%) are as a result of direct extension of a pulmonary parenchymal infection 
into the pleural space.
1, 3     
Empyema in HIV infected patients is uncommon in developed 
countries despite the increased risk HIV infection confers to the development of respiratory 
infections.
8, 9
  In this series, at an ecological level there appears to be a strong association 
between HIV infection and the development of empyema with a disproportionate number of 
patients with empyema being HIV infected. 
The microbiology of empyema is vast.  Common pathogens include S. pneumoniae, 
Staphylococcus aureus, Streptococcus anginosus, Streptococcus pyogenes, Prevotella spp. 
and M. tuberculosis.
3
   Since the availability of antibiotics the bacteriology has changed; S. 
pneumonia and S. pyogenes infections occur less, and S. aureus and enteric Gram-negative 
organisms occur more frequently.
10, 11
   Infections caused by Gram-negative organisms occur 
more frequently in HIV infected patients
8
 and a trend was found in our series.
 
  Infection with 
non-typhoidal salmonella is well described in patients with advanced HIV infection,
12
 
bacteraemia occurs frequently however pleuropulmonary complications are rare, with 
empyema usually occurring in the setting of CD4 counts <100 cells/mm
3
.
13, 14
    The 
incidence of non-typhoidal salmonella reported in our series suggests that non-typhoidal 
salmonella should be considered potential aetiological organisms in HIV infected patients 
with low CD4 cell counts.  The identification of Pseudomonas aeruginosa and Acinetobacter 
baumannii as causes of empyema is worrying and may reflect the increased contact HIV 
infected patients have with health facilities.   There appears to be a resurgence of important 
13 
 
pathogens from the pre-antibiotic era in the presence of the HIV pandemic with S. pneumonia 
being the most frequent identified bacterial agent in the HIV infected patients in this series.
 
Tuberculous empyema has been reported at frequencies of 3-6% in developed countries,
7, 8, 15
 
however in developing countries TB accounts for up to 35% of cases.
4
  In Southern Africa, 
the majority of patients with tuberculous empyema are HIV infected.
16
    Rates of tuberculous 
empyema are higher in our series than those stated in developed countries; when combining 
the patients with proven and clinical TB, 44.2% of empyemas were attributed to tuberculous 
infection.  HIV infected patients tend to be given the diagnosis of clinical TB when no 
microbiological aetiology is found despite extensive investigation, we attribute this to 
clinician bias in a community where rates of HIV and TB co-infection are high.  Dual 
infections were only found in patients with HIV infection and occurred over a range of CD4 
counts (39-382 cells/mm
3
).  
Pleural involvement is unusual with NTM; pleural thickening adjacent to pulmonary 
parenchymal infection is described, pleural effusions if present are small.
17, 18
  Empyema is 
rare with only one report of a clearly documented empyema due to NTM in a patient with 
advanced acquired immunodeficiency syndrome.
19
  NTM were cultured in two patients 
(Mycobacterium  avium-intracellulare in one, failed identification of species in the other due 
to contamination), both were HIV infected with advanced disease; CD4 counts of 7 and 25 
cells/mm
3
 and neither was on antiretroviral therapy.  
Despite thorough investigation no identifiable microbiological aetiology for empyema was 
identified in 23.3%; patients may have been treated with antibiotics prior to admission or 
specimens for anaerobic cultures may not have been optimally processed thus underreporting 
anaerobic infections.  Anaerobic bacteria remain important pathogens in adults.
20
   Rapid 
14 
 
transfer in oxygen-free media to the laboratory and adequate anaerobic culture techniques are 
vital to increase diagnostic sensitivity.
10
   
The treatment of empyema depends upon the pathophysiological stage in which the patient 
presents.  Empyemas in the exudative stage, may be successfully drained via closed tube 
thoracostomy.
7, 21, 22
  Empyemas in the fibrinopurulent stage often require more aggressive 
drainage procedures or video-assisted thoracoscopy.
21, 22, 23
  There is contradictory evidence 
on the use of intrapleural fibrinolytics; they may be used as an adjunct to closed tube 
thoracostomy however do not reduce mortality or the need for surgery.
24, 25  
Thoracoscopic 
drainage procedures are popular; with less post operative pain, lower costs, shorter hospital 
stays and better cosmetic results.
24, 26
  Optimal timing is important as high failure rates have 
been reported in cases with advanced empyema.
27, 28
  Empyema in the organisational stage is 
best managed via open surgery; decortication, thoracostomy or thoracoplasty to manage 
extensive pleural peel or control the underlying inflammatory process.
7, 21, 23
  Decortication 
remains the modality of choice for treating advanced empyema, thoracoplasty and 
thoracostoma are reserved for debilitated patients who cannot tolerate aggressive surgery or 
those in whom decortication has failed.
21, 29
  Our cardiothoracic surgeons offer a less 
aggressive option, with pleural toilette and the placement of a basal drain prior to considering 
the usual definitive procedures, described in the literature, for the management of 
complicated empyema.  The success rate of closed tube thoracostomy for advanced or 
loculated empyema is low 
7, 21
 and the mortality of empyema treated by closed tube 
thoracostomy is high, 11-24%.
21, 29
 
In our series 30.4% of patients were successfully treated via closed tube thoracostomy, 
however many required multiple tubes or prolonged drainage.  Cardiothoracic intervention as 
a primary therapeutic measure was offered to only 6 (3.5%) patients, surgery was later 
offered to another 46 (26.7%).  Development of local complications in 15 (28.9%) patients or 
15 
 
the necessity for multiple tube insertions in 15 (28.9%) appeared to be the criteria for surgery.  
Surgery was more readily offered to patients on antiretroviral therapy. 
Long-term open tube thoracostomy via a tube thoracostomy cut short and the placement of a 
colostomy bag over the cut end of the tube is a technique (which we could not find described 
in the literature) used due to limited cardiothoracic resources available to us. The empyema 
space is allowed to drain freely and with regular withdrawal of the tube, the pleural space 
eventually obliterates.  Of the 47 patients discharged with open tube thoracostomas, we were 
able to assess the outcomes in 38%.  Of these, 11 (61%) patients had ultimate resolution, thus 
open tube thoracostomy may be a viable alternate treatment option in settings with limited 
cardiothoracic services.  The high rate of patients lost to follow up doesn’t allow for accurate 
assessment, however it is an intriguing alternative treatment and further prospective studies 
should be undertaken to assess this method further.   
A significant proportion of patients refused hospital treatment; they had either required 
multiple tube insertion or waited for long periods of time for cardiothoracic intervention.  
Mortality in this series is in line with that of current literature, but may be underreported 
considering many patients refused hospital treatment or were lost to follow up.   
Although this is a very large retrospective case series of empyema in HIV infected patients, 
this study is limited by the sample size of the subgroups and may not have had sufficient 
power to show statistical significance between the various groups.  The fact that 
cardiothoracic surgery was offered largely only to patients on antiretroviral therapy is a 
further limitation as we were only able to assess whether patients underwent surgery as 
opposed to the need, as described in the literature, for cardiothoracic intervention.  Only 
subjects referred to the respiratory unit were analysed and subjects with uncomplicated 
courses may have been excluded.   
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CONCLUSION 
 
This is the largest series of empyema in HIV infected patients.  It suggests that HIV infection 
is strongly associated with the development of empyema.  We were unable to show that HIV 
alters the aetiology of empyema however a trend towards infection with enteric Gram-
negative organisms in particular Salmonella spp. was found and a further case of NTM 
empyema is described.  Clinical outcomes were similar in HIV infected and non-infected 
patients.  Bias towards patients on antiretroviral therapy with regards to surgical intervention 
exists; and may translate to shorter length of stay or even reduced mortality. 
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Appendix D 
 
Comparison of empyema thoracis in HIV infected and non-infected patients with regards to 
aetiology and outcome. 
 
Empyema thoracis in HIV infection.                                                                                                                                                                                    
 
ABSTRACT 
Background:  Empyema thoracis remains a problem in developing countries.  Human 
Immunodeficiency Virus (HIV) is a risk factor for the development of empyema.  There is a 
clinical impression that HIV infected patients with empyema have worse outcomes.  This 
study was conducted to assess whether HIV infection affected aetiology or outcomes of 
patients with empyema. 
Methods:  A retrospective review was conducted of patients, meeting established criteria for 
the diagnosis of empyema, admitted to Chris Hani Baragwanath Hospital (CHBH) from 
January 2006 to December 2009.  HIV infected and non-infected patients were evaluated for 
differences in aetiology and outcomes including; length of stay, need for surgical intervention 
and local complications of closed tube thoracostomy.  A sub analysis of HIV infected patients 
stratified according to CD4 cell count and antiretroviral use was also performed. 
Results:   One hundred and seventy two patients were included, 125 (73%) were HIV 
infected and 47 (27%) were HIV non-infected.  HIV infected patients with lower CD4 cell 
counts were more likely to be diagnosed with clinical tuberculosis.  The aetiology of 
empyema was more commonly not determined in HIV non-infected patients.  HIV infected 
patients on antiretrovirals were more likely to have definitive surgery and had shorter hospital 
stays than those not on antiretrovirals. 
Conclusions:  This study failed to demonstrate any significant differences in aetiology 
among HIV infected versus non-infected patients with empyema.  There was a trend towards 
more Gram-negative infections in the HIV infected group.  Antiretroviral use was associated 
with improved outcomes with regards to cardiothoracic intervention and length of stay.  
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INTRODUCTION 
Empyema thoracis; the presence of pus in the pleural space,
1, 2, 3 
remains a problem in 
developing countries,
4
 its course is often prolonged and frequently requires surgical drainage.  
HIV infection is a risk factor for empyema
1
 and complicates pneumonia more frequently in 
HIV infected patients.
5
   Reported risk factors for the development of empyema include 
serum albumin <30 g/dl, intravenous drug use, ethanol abuse, younger age, male sex and 
current smoking. 
6 
At CHBH, an academic hospital with 847 medicine beds in Soweto, South Africa, majority of 
patients with empyema are HIV infected and present with late stages of empyema.  Despite 
expected low success rates of closed tube thoracostomy in the treatment of late empyema
7
 it 
remains first-line therapy at our hospital as cardiothoracic services are limited and many 
patients are critically ill and unable to tolerate aggressive surgical procedures.   
There is an impression that HIV infected patients do worse clinically.  Limited literature 
exists to support this, some reports claim patients with CD4 counts <200 cells/mm
3 
have 
higher complication rates and a poorer prognosis.
5
 
This study compares microbiological aetiology, outcomes including; length of stay, need for 
surgical intervention and local complications of tube thoracostomy, in patients with empyema 
according to HIV status.  A secondary objective is to compare aetiology and outcomes in 
patients with HIV infection stratified according to CD4 cell count (≥200 cells/mm3 or <200 
cells/mm
3
) and antiretroviral usage. 
 
METHODS 
The CHBH Respiratory Unit database from January 2006 to December 2009 was reviewed.  
This Excel (Microsoft Corporation, Bellevue, WA) database is compiled from discharge 
summaries and case notes of patients referred to the Respiratory Unit.   Permission to use the 
database was obtained from the database manager and permission to conduct this review was 
obtained by the Human Research Ethics committee of the University of the Witwatersrand. 
Patients meeting established criteria of empyema; aspiration of pus from the pleural space, 
pleural fluid pH <7.2, pleural fluid glucose <3.4 mmol/l (60 mg/dl) or positive microbial stain 
and/or culture, 
1, 2 
were included.  Of the 250 records reviewed, 78 patients were excluded 
(fig 1).   
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250 Records Reviewed 
 Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Flowchart summarising patient inclusion. 
 
 
Patients were divided into aetiological groups based upon initial pleural fluid results: [1] 
proven tuberculosis (TB), [2] clinical TB, [3] dual, [4] bacterial, [5] non-tuberculous 
mycobacteria (NTM) and [5] unknown.  For proven TB either pleural fluid or sputum 
samples demonstrated Acid-Fast Bacilli (AFB) on microscopy and/or cultured 
Mycobacterium tuberculosis or pleural biopsy demonstrated histological features of 
tuberculous infection.  Patients with radiological features of TB, those in whom clinical 
suspicion of TB existed or responded to a trial of anti-tuberculous therapy were classified as 
clinical TB.  Patients diagnosed with proven TB who also cultured a bacterial organism were 
classified as dual.  Patients with bacterial infections were subdivided into Gram-positive, 
Gram-negative and polymicrobial infections.  Patients in whom pleural fluid analysis or 
histology failed to identify a microbiological aetiology were classified as unknown. 
19 On Antiretroviral therapy 
88 CD4 count <200 cells/mm
3
 
125 HIV Infected 
47 HIV non-infected 172 Patients included 
78 Patients Excluded:                              
- 29 Unresolved / Chronic empyema                            
- 19 Insufficient Data                                                                          
 - 7 HIV status unknown                                          
 - 12 No smoking or ethanol history 
- 13 Iatrogenic empyema                                         
- 8 Sub-diaphragmatic pathology                    
- 3 Malignant effusions                                   
- 2 Penetrating chest trauma                           
- 1 Not biochemically empyema                     
- 1 Post thoracic surgery                                      
- 2 Chest wall abscess, not empyema 
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Outcomes were defined as: [1] resolution of empyema via closed tube thoracostomy in ≤14 
days, [2] resolution of empyema via closed tube thoracostomy but requiring insertion of 
multiple tubes or prolonged drainage (>14 days), [3] long-term open tube thoracostomy, [4] 
definitive cardiothoracic intervention and [5] death.  Length of stay was compared among 
each group. 
Complications were defined as:  [1] wound sepsis at tube thoracostomy site and [2] secondary 
infection of the pleural space. 
Statistical analysis was performed using STATA 10 software (StataCorp LP, College Station, 
Texas).  Univariate analyses were performed in each of the groups against known risk factors 
for empyema; age, smoking, ethanol abuse and male sex.   Association between categorical 
variables were tested using Fisher’s exact test, odds ratios and 95% confidence intervals were 
calculated.  Continuous variables with parametric distributions were tested with the student’s 
t-test, those with nonparametric distributions with the Wilcoxin Rank Sum test.  Where 
significant risk factors were identified between groups, they were analysed using multivariate 
regression analyses.  Significance was considered as a P value of <0.05. 
 
RESULTS 
In total 172 patients were included, mean age was 39 (14-78).  The study group comprised 
110 (64%) males.  Using all cause admissions to the medical wards during the study period, it 
was found that males were at greater risk of developing empyema (p <0.0001, OR 2.40, 95% 
CI 2.00-2.88).  HIV infection was present in 125 (73%) patients.  Using a HIV prevalence in 
Gauteng of 12.5%, 
8
 HIV infection was confirmed as a risk factor for the development of 
empyema (p <0.0001, OR 18.55, 95% CI 14.60-23.60).  Amongst the HIV infected group, 
median CD4 count was 128cells/mm
3 
(1-885 cells/mm
3
, IQR 62-219 cells/mm
3
), 88 (70.4%) 
had a CD4 count <200 cells/mm
3 
and 19 (15.2%) were on antiretroviral therapy.   
With regards the reported risk factors for the development of empyema, statistical differences 
were found among the HIV infected and non-infected groups for age (p = 0.0003) and sex    
(p = 0.05).  In HIV infected patients stratified according to CD4 cell count, ethanol abuse was 
found to be significant (p = 0.04).  No differences in risk factors were found in HIV infected 
patients stratified according to antiretroviral usage.  
Microbiological aetiologies were as follows; 34 (19.8%) patients had proven TB, 34 (19.8%) 
had clinical TB, 8 (4.7%) had dual infections, 55 (32%) had bacterial infections, 1 (0.6%) had 
NTM infection, and in 40 (23.3%), no microbiological aetiology was identified.  One patient 
cultured both Streptococcus pneumoniae and NTM and was classified as bacterial. We report 
5 cases of Salmonella non-typhi empyema, all five patients were HIV infected; four had CD4 
counts <100 cells/mm
3
, the fifth was on antiretroviral therapy with a CD4 count of 118 
cells/mm
3
.  Pleural fluid cultured Salmonella spp. in all five, in one Salmonella spp. was also 
cultured on sputum (Table 1). 
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Table 1 
Microbiological aetiologies by HIV Status 
 
 HIV Positive (n=125) HIV Negative (n=47) 
   
* Proven Tuberculosis:  34 (27.2%) 8 (17%) 
 Pleural Fluid Microscopy AFB positive 7 (20.6%) 0 
 Pleural Fluid culture MTB positive  18 (53.0%) 1 (12.5%) 
 Sputum Microscopy AFB positive 12 (35.5%) 4 (50%) 
 Sputum Culture MTB positive 9 (26.5%) 2 (25%) 
Blood Culture MTB positive  3 (8.8%) 0 
 Pleural Biopsy consistent with tuberculosis 2 (5.9%) 2 (25%) 
   
Clinical Tuberculosis: 27 (21.6%) 7 (14.9%) 
   
* Bacterial Infection: 53 (42.4%) 10 (21.3%) 
 S. pneumoniae 22 (41.5%) 3 (30%) 
S. anginosus (formerly S. milleri) 5 (9.4%) 5 (50%) 
K. pneumonia 5 (9.4%) 1 (10%) 
 Salmonella spp. 5 (9.4%) 0 
S. aureus 3 (5.7%) 0 
Peptostreptococcus spp. 3 (5.7%) 1 (10%) 
 E. coli 3 (5.7%) 0 
Prevotella spp. 2 (3.8%) 3 (30%) 
Nocardia spp. 2 (3.8%) 0 
H. influenza 2 (3.8%) 0 
P. mirabilis 2 (3.8%) 0 
 P. aeruginosa 2 (3.8%) 0 
E. faecium 1 (1.9%) 0 
 E. faecalis 1 (1.9%) 0 
 S. viridans 1 (1.9%) 0 
S. pyogenes 1 (1.9%) 0 
A. baumannii 1 (1.9%) 0 
 Streptococcus Group F 1 (1.9%) 0 
Streptococcus Group C 0 1 (10%) 
   
Non-tuberculous mycobacteria: 1 (0.8%) 0 
 Mycobacterium avium-intracellulare complex 1 (0.8%) 0 
   
Unknown: 18 (14.4%) 22 (46.8%) 
   
MTB = Mycobacterium tuberculosis 
* Includes those with dual infection. 
Proof of MTB often obtained by more than one method. 
Polymicrobial infection in 13 patients. 
 
With regards aetiology; HIV non-infected patients more often had no identifiable 
microbiological aetiology identified whereas HIV infected patients with lower CD4 cell 
counts had a significantly greater likelihood of being diagnosed with clinical TB and showed 
a trend towards having a greater incidence of infections caused by Gram-negative organisms 
(OR 10.6).  Antiretroviral therapy did not alter the aetiology of empyema (Table 2).      
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Table 2 
Differences in aetiology of empyema 
 
   P OR (95% CI) 
     
† HIV infected versus non infected patients: HIV Negative (n=47) HIV Positive (n=125)   
 Proven tuberculosis 8 34 0.58 1.29 (0.52 – 3.2) 
 Clinical tuberculosis 7 27 0.27 1.71 (0.65 – 4.45) 
 Dual Infection 0 8 * * 
 Bacterial Infection 10 45 0.08 2.10 (0.91 – 4.82) 
 - Gram-positive 5  31 0.94 0.94 (0.21 – 4.30) 
 - Gram-negative 1 13 0.09 10.60 (0.72 – 156.07) 
 - Polymicrobial 4 9 0.10 0.25 (0.51 – 1.27) 
 Non-tuberculous mycobacteria 0 1 * * 
 Unknown aetiology 22 18 <0.005 0.18 (0.08 – 0.40) 
     
‡ CD4 <200 versus ≥200 cells/mm3: CD4 < 200 (n=88) CD4 ≥ 200 (n=37)   
 Proven tuberculosis 26 8 0.08 0.36 (0.11 – 1.37) 
 Clinical tuberculosis 14 13 0.02 2.98 (1.22 – 7.30) 
 Dual Infection 4 4 0.26 2.33 (0.54 – 10.07) 
 Bacterial Infection 36 9 0.08 0.46 (0.19 – 1.09) 
 Non-tuberculous mycobacteria 1 0 * * 
 Unknown aetiology 11 7 0.30 1.75 (0.61 – 5.00) 
     
¤ ART versus no ART: ART (n=19) ART (n=106)   
 Proven tuberculosis 6 28 0.78 1.29 (0.36 – 4.06) 
 Clinical tuberculosis 7 20 0.13 2.51 (0.73 – 7.94) 
 Dual Infection 0 8 * * 
 Bacterial Infection 3 42 0.07 0.29 (0.05 – 1.10) 
 Non-tuberculous mycobacteria 0 1 * * 
 Unknown aetiology 3 15 0.74 1.14 (0.19 – 4.72) 
     
ART = Antiretroviral therapy 
* P value, odds ratios and 95% confidence intervals were not calculated in groups which included a zero. 
† Adjusted in logistic regression analysis for age and sex. 
‡ Adjusted in logistic regression analysis for ethanol abuse. 
¤ Univariate analysis using 2-tailed Fisher’s exact test.
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Tube thoracostomas were inserted in the general medical wards in all but 11 (6.4%) patients; 
6 (3.5%) were transferred to cardiothoracic surgeons as their pleural collections were not 
amenable to tube thoracostomy, 3 (1.8%) had very small collections which were treated 
medically and 2 (1.2%) refused further hospital treatment.   
Following closed tube thoracostomy; 16 (10%) patients had complete resolution of empyema 
within 14 days, 34 (20.4%) had resolution with prolonged drainage or multiple tubes.  
Following 14 days of closed tube thoracostomy, 47 (28.1%) were discharged home with an 
open tube thoracostoma; 14 (29.8%) of these following basal tube insertion by cardiothoracic 
surgeons.  Definitive cardiothoracic intervention was required in 38 (22.8%); 35 had pleural 
toilette and basal tube insertion with subsequent resolution, 1 had a decortication, and 2 
required thoracostomy.  Prior to resolution of empyema, 14 (8.3%) patients refused further 
treatment and discharged themselves from hospital.   
Of the patients converted to open tube thoracostomy; 6 (12.8%) were followed up by 
cardiothoracic services, 11 (23.4%) had resolution of empyema, 23 (48.9%) defaulted follow 
up, 5 (10.6%) were transferred to cardiothoracic surgeons for a definitive procedure; toilette, 
decortication, thoracostomy or thoracoplasty and 2 (4.3%) demised due to ongoing pleural 
sepsis.  
Overall length of stay was a median of 29 days (3-118 days).  No differences were found with 
regards to length of stay between HIV infected and non-infected patients or between those 
stratified according to CD4 cell count.  Patients on antiretroviral therapy had significantly 
shorter lengths of stay. 
Patients were evaluated for development of complications; 4 (2.4%) developed wound sepsis 
at tube thoracostomy site and 26 (15.6%) developed secondary infection of their pleural 
space.  Mortality in this series was 12.8% (22/172).  
Regarding outcomes and complications; HIV infected patients on antiretrovirals are more 
likely to be offered definitive cardiothoracic intervention.  Length of stay was shorter and, 
though not statistically significant, there were no mortalities amongst patients on 
antiretroviral therapy.  No other differences were found between the various groups (Table 
3).
27 
 
Table 3 
Differences in outcomes and complications of empyema 
 
   P OR (95%) 
     
† HIV infected versus non infected patients: HIV Negative (n=47) HIV Positive (n=125)   
 § Length of stay  27 (4 – 94) 29 (3 – 118) 0.65  
 Resolution Simple 4 12 0.78 0.83 (0.24 – 2.88) 
 Resolution Complicated 8 26 0.50 1.38 (0.54 – 3.52) 
 Long term open tube thoracostomy 13 32 0.80 0.90 (0.41 – 1.99) 
 Definitive surgical intervention  12 26 0.42 1.13 (0.31 – 1.62) 
 Death 6 16 0.80 0.78 (0.40 – 3.40) 
 Wound sepsis at tube thoracostomy site 1 3 0.88 1.21 (0.10 – 14.72) 
 Secondary infection of pleural space 5 21 0.17 2.19 (0.71 – 6.71) 
     
‡ CD4 <200 versus ≥200 cells/mm3: CD4 < 200 (n=88) CD4 ≥ 200 (n=37)   
 § Length of stay  29 (4 – 118) 31 (3 – 88) 0.73  
 Resolution Simple 8 4 0.84 1.14 (0.32 – 4.09) 
 Resolution Complicated 18 8 0.82 1.11 (0.43 – 2.90) 
 Long term open tube thoracostomy 23 9 0.98 0.99 (0.40 – 2.45) 
 Definitive surgical intervention  18 8 0.89 1.07 (0.42 – 2.75) 
 Death 14 2 0.10 0.27 (0.06 – 1.30) 
 Wound sepsis at tube thoracostomy site 3 0 * * 
 Secondary infection of pleural space 15 6 0.82 1.00 (0.99 – 1.00) 
     
¤ ART versus no ART: ART (n=19) ART (n=106)   
 § Length of stay  37 (19 – 71) 27 (3 – 118) 0.05  
 Resolution Simple 1 11 0.69 0.47 (0.01 – 3.60) 
 Resolution Complicated 4 22 1.00 0.98 (0.22 – 3.52) 
 Long term open tube thoracostomy 5 27 1.00 1.01 (0.26 – 3.32) 
 Definitive surgical intervention  8 18 0.03 3.43 (1.03 – 10.90) 
 Death 0 16 * * 
 Wound sepsis at tube thoracostomy site 1 2 0.39 2.89 (0.05 – 57.56) 
 Secondary infection of pleural space 2 19 0.74 0.54 (0.06 – 2.61) 
     
ART = Antiretroviral therapy                 ‡ Adjusted in logistic regression analysis for ethanol abuse. 
* P value, odds ratios and 95% confidence intervals were not calculated in groups which included a zero.          ¤ Univariate analysis using 2-tailed Fisher’s exact test. 
† Adjusted in logistic regression analysis for age and sex.              § Length of stay adjusted in linear regression analysis.
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DISCUSSION 
Empyema thoracis remains an important problem in South Africa.  Majority of empyemas 
(>50%) are as a result of direct extension of a pulmonary parenchymal infection into the 
pleural space.
1, 3     
Empyema in HIV infected patients is uncommon in developed countries 
despite the increased risk HIV infection confers to the development of respiratory 
infections.
9, 10
   
The microbiology of empyema is vast.  Common pathogens include S. pneumoniae, 
Staphylococcus aureus, Streptococcus anginosus, Streptococcus pyogenes, Prevotella spp. 
and M. tuberculosis.
3
   Since the availability of antibiotics the bacteriology has changed; S. 
pneumonia and S. pyogenes infections occur less, and S. aureus and enteric Gram-negative 
organisms occur more frequently.
11, 12
   Infections caused by Gram-negative organisms occur 
more frequently in HIV infected patients
9
 and a trend which was found in our series.
 
  
Infection with non-typhoidal salmonella is well described in patients with advanced HIV 
infection,
13
 bacteraemia occurs frequently however pleuropulmonary complications are rare, 
with empyema usually occurring in the setting of CD4 counts <100 cells/mm
3
.
14, 15
    The 
incidence of non-typhoidal salmonella reported in our series suggests that non-typhoidal 
salmonella should be considered potential aetiological organisms in HIV infected patients 
with low CD4 cell counts.  The identification of Pseudomonas aeruginosa and Acinetobacter 
baumannii as causes of empyema is worrying and may reflect the increased contact HIV 
infected patients have with health facilities.   There appears to be a resurgence of important 
pathogens from the pre-antibiotic era in the presence of the HIV pandemic.
 
Tuberculous empyema has been reported at frequencies of 3-6% in developed countries,
7, 9, 16
 
however in developing countries TB accounts for up to 35% of cases.
4
  In Southern Africa, 
majority of patients with tuberculous empyema are HIV infected.
17
    Rates of tuberculous 
empyema are higher in our series than those stated in developed countries; when combining 
the patients with proven and clinical TB, 44.2% of empyemas were attributed to tuberculous 
infection.  HIV infected patients tend to be given the diagnosis of clinical TB when no 
microbiological aetiology is found despite extensive investigation, we attribute this to 
clinician bias in a community where rates of HIV and TB co-infection are high.  Dual 
infections were only found in patients with HIV infection and occurred over a range of CD4 
counts (39-382 cells/mm
3
).  
Pleural involvement is unusual with NTM; pleural thickening adjacent to pulmonary 
parenchymal infection is described, pleural effusions if present are very small.
18, 19
  Empyema 
is rare with only one report of a clearly documented empyema due to NTM in a patient with 
advanced acquired immunodeficiency syndrome.
20
  NTM were cultured in two patients 
(Mycobacterium  avium-intracellulare in one, failed identification of species in the other due 
to contamination), both were HIV infected with advanced disease; CD4 counts of 7 and 25 
cells/mm
3
 and neither was on antiretroviral therapy.  
Despite thorough investigation no identifiable microbiological aetiology for empyema was 
identified in 23.3%; patients may have been treated with antibiotics prior to admission or 
specimens for anaerobic cultures may not have been optimally processed thus underreporting 
anaerobic infections.  Anaerobic bacteria remain important pathogens in adults.
21
  Rapid 
transfer in oxygen-free media to the laboratory and adequate anaerobic culture techniques are 
vital to increase diagnostic sensitivity.
11
   
The treatment of empyema depends upon the pathophysiological stage in which the patient 
presents.  Empyemas in the exudative stage, may be successfully drained via closed tube 
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thoracostomy.
7, 22, 23
  Empyemas in the fibrinopurulent stage often require more aggressive 
drainage procedures or video-assisted thoracoscopy.
22, 23, 24
  There is contradictory evidence 
on the use of intrapleural fibrinolytics; they may be used as an adjunct to closed tube 
thoracostomy however do not reduce mortality or the need for surgery.
25, 26  
Thoracoscopic 
drainage procedures are popular; less post operative pain, lower costs, shorter hospital stays 
and better cosmetic results.
25, 27
  Optimal timing is important as high failure rates have been 
reported in cases with advanced empyema.
28, 29
  Empyema in the organisational stage is best 
managed via open surgery; decortication, thoracostomy or thoracoplasty to manage extensive 
pleural peel or control the underlying inflammatory process.
7, 22, 24
  Decortication remains the 
modality of choice for treating advanced empyema, thoracoplasty and thoracostoma are 
reserved for debilitated patients who cannot tolerate aggressive surgery or those in whom 
decortication has failed.
22, 30
  The success rate of closed tube thoracostomy for advanced or 
loculated empyema is low 
7, 22
 and the mortality of empyema treated by closed tube 
thoracostomy is high, 11-24%.
22, 30
 
In our series 30.4% of patients were successfully treated via closed tube thoracostomy, 
however many required multiple tubes or prolonged drainage.  Cardiothoracic intervention as 
a primary therapeutic measure was offered to only 6 (3.5%) patients, surgery was required in 
another 46 (26.7%).  Of the 52 patients requiring surgery, 38 (22.1%) had definitive surgery, 
14 (8.1%) were discharged home with open tube thoracostomas and 2 (3.9%) demised.  
Development of local complications in 15 (28.9%) patients or the necessity for multiple tube 
insertions in 15 (28.9%) appeared to be the criteria for surgery.  Surgery was more readily 
offered to patients on antiretroviral therapy. 
Long-term open tube thoracostomy via a tube thoracostomy cut short and the placement of a 
colostomy bag over the cut end of the tube is a technique (which we could not find described 
in the literature) used due to limited cardiothoracic resources available to us. The empyema 
space is allowed to drain freely and with regular withdrawal of the tube, the pleural space 
eventually obliterates.  Of the 47 patients discharged with open tube thoracostomas, we were 
able to assess the outcomes in 38%.  Of these, 11 (61%) patients had ultimate resolution, thus 
open tube thoracostomy may be a viable alternate treatment option in settings with limited 
cardiothoracic services.  The high rate of patients lost to follow up doesn’t allow for accurate 
assessment, however it is an intriguing alternative treatment and further prospective studies 
should be undertaken to assess this method further.   
A significant proportion of patients refused hospital treatment; they had either required 
multiple tube insertion or waited for long periods of time for cardiothoracic intervention.  
Mortality in this series is in line with that of current literature, but may be underreported 
considering many patients refused hospital treatment or were lost to follow up.   
 
 CONCLUSION 
This is the largest series of empyema in HIV infected patients.  It confirms that HIV infection 
is a risk factor for the development of empyema.  We were unable to show that HIV alters the 
aetiology of empyema however a trend towards infection with enteric Gram-negative 
organisms in particular Salmonella spp. was found and a further case of NTM empyema is 
described.  Clinical outcomes were similar in HIV infected and non-infected patients.  Bias 
towards patients on antiretroviral therapy with regards to surgical intervention exists; and 
may translate to shorter length of stay or even reduced mortality. 
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Appendix E 
 
Dear Authors 
 
Thank you for your revised manuscript which will be acceptable pending minor 
changes suggested by the reviewers. Please may I ask that you revise the 
manuscript according to the guidelines given by the reviewers underneath, as 
appropriate, or give reasons where you do not make such changes. 
 
Please make all the changes with *tracking* in WORD switched on, and upload a 
new version on our website, following the procedure underneath; 1. Go to 
http://www.sajei.co.za and log in with your username and password; 2. Click on 
your “AUTHOR” profile; 3. Click on the name of your manuscript and go to the 
REVIEW tab; 4. Upload the new version in the upload box in the EDITOR’S 
DECISION section; 5. Please compose a letter that includes the query by the 
reviewer, how the author has dealt with the query and please state and 
highlight the change in the manuscript. 
5. Click on “NOTIFY THE EDITOR” after that and send me a short message to that 
effect. 
 
We would like to receive your revised manuscript within 1 week of today's 
date, i.e. 25 January 2012. 
 
I look forward to receiving the revised draft of your manuscript.  
 
Yours sincerely 
Prof H Koornhof 
Editor: SAJEI 
 
Email: toc@sajei.co.za 
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Reviewer B: 
This large retrospective case series of empyema provides interesting local 
data on aetiology by HIV status and outcomes. The discussion needas a 
paragraph on study limitations - notably th fact that surgery seems to largely 
only have been offered to HIV+ patients on ART & that need for surgery cannot 
be assessed in a retrospective study like this.  
 
Specific comments: 
Abstract will need amending after analyses have been revised (see below) Line 
45 - this sentence should be moved to methods with more detail on the nature 
of the hospital, only the practice at CHBH should be included Line 53 need for 
surgery cannot be assessed in this study - only whether surgery was done can 
be recorded Line 61 reword: "An Excel (Microsoft Corporation, Bellevue, WA) 
database iwas compiled..." 
Line 67 were pH & glucose required or "or"? Delete non-SI glucose units Line 
69 Unclear why 29 Unresolved / Chronic empyema were excluded given that one 
outcome isf long-term open tube thoracostomy. 
Line 98 specily that dual means TB & bacterial. 
Line 104 I assume culture was from pleural specimen - specify Line 120 
Wilcoxon  is mis-spelled 
Results: a table of patient characteristics by HIV status should be included & 
much of the text in the 1st 2 paragraphs then becomes superfluous Line 129 
Inappropriate to statistically analyse HIV prevalence in community & patients 
- delete (point can be made in discussion) Table 2 I do not see the value of 
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this table as detailed aetiology is given in table 1 & feel that providing ORs 
& P for every line is uninformative. 
The table should be revised to show only pooled analyses of aetiology  (eg all 
TB, all bacterial, unknown) - by the way under ART the 2nd column heading 
should be "No ART" (same error in table 3) - also specify that CD4 was only 
done in HIV+. 
Results after table 2 (line numbering disappears at this point, which is 
irritating - tables & figures should be at the end of manuscripts): 
Page 7 paragraph 2 sentence 3 should read "Definitive cardiothoracic 
intervention was required done in...:Definitive cardiothoracic intervention 
was required done in..."; last paragraph 1st sentence should read "...HIV 
infected patients on antiretrovirals weare more likely to be offeredundergo 
definitive cardiothoracic intervention" 
 
------------------------------------------------------ 
Reviewer C: 
When seeing the title, I was immediately interested inreading further. The 
content did not disappoint! 
Very interesting article, well written, concise. 
 
The article illustrates the fact that over the course of the HIV epidemic, 
we've accumulated a wealth of clinical experience and case series. 
Unfortunately the time is seldom found to write it up and share that 
experience with other clinicians. The authors should be commended for taking 
the time to collect the data (albeit retrospectively), do the analysis and 
write it up. It is much appreciated! 
 
------------------------------------------------------ 
________________________________________________________________________ 
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Appendix F 
Comparison of empyema thoracis in HIV infected and non-infected patients with regards to 
aetiology and outcome. 
 
Empyema thoracis in HIV infection.                                                                                                                                                                                    
 
ABSTRACT 
Background:  Empyema thoracis remains a problem in developing countries.  Human 
Immunodeficiency Virus (HIV) is a risk factor for the development of empyema.  There is a 
clinical impression that HIV infected patients with empyema have worse outcomes.  This 
study was conducted to assess whether HIV infection affected aetiology or outcomes of 
patients with empyema. 
Methods:  A retrospective review was conducted of patients, meeting established criteria for 
the diagnosis of empyema, admitted to Chris Hani Baragwanath Hospital (CHBH) from 
January 2006 to December 2009.  HIV infected and non-infected patients were evaluated for 
differences in aetiology and outcomes including; length of stay,  surgical intervention and 
local complications of closed tube thoracostomy.  A sub analysis of HIV infected patients 
stratified according to CD4 cell count and antiretroviral use was also performed. 
Results:   One hundred and seventy two patients were included, 125 (73%) were HIV 
infected and 47 (27%) were HIV non-infected.  HIV infected patients with lower CD4 cell 
counts were more likely to be diagnosed with clinical tuberculosis.  The aetiology of 
empyema was more commonly not determined in HIV non-infected patients.  HIV infected 
patients on antiretrovirals were more likely to have thoracic surgery and had shorter hospital 
stays than those not on antiretrovirals. 
Conclusions:  This study failed to demonstrate any significant differences in aetiology 
among HIV infected versus non-infected patients with empyema.  There was a trend towards 
more Gram-negative infections in the HIV infected group.  Antiretroviral use was associated 
with improved outcomes with regards to cardiothoracic intervention and length of stay.  
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INTRODUCTION 
Empyema thoracis; the presence of pus in the pleural space,
1, 2, 3 
remains a problem in 
developing countries,
4
 its course is often prolonged and frequently requires surgical drainage.  
HIV infection is a risk factor for empyema
1
 and complicates pneumonia more frequently in 
HIV infected patients.
5
   Reported risk factors for the development of empyema include 
serum albumin <30 g/dl, intravenous drug use, ethanol abuse, younger age, male sex and 
current smoking. 
6 
In our experience, majority of patients with empyema are HIV infected and present with late 
stages of empyema.  Despite expected low success rates of closed tube thoracostomy in the 
treatment of late empyema
7
 it remains first-line therapy at our hospital as cardiothoracic 
services are limited and many patients are critically ill and unable to tolerate aggressive 
surgical procedures.   
There is an impression that HIV infected patients do worse clinically.  Limited literature 
exists to support this, some reports claim patients with CD4 counts <200 cells/mm
3 
have 
higher complication rates and a poorer prognosis.
5
 
This study compares microbiological aetiology, outcomes including; length of stay, whether 
surgical intervention was offered and local complications of tube thoracostomy, in patients 
with empyema according to HIV status.  A secondary objective is to compare aetiology and 
outcomes in patients with HIV infection stratified according to CD4 cell count (≥200 
cells/mm
3
 or <200 cells/mm
3
) and antiretroviral usage. 
 
METHODS 
CHBH is a large academic hospital in Soweto Johannesburg, with 847 medical beds.  It is the 
only in-patient facility for the greater Soweto area and serves as a referral centre for Southern 
Gauteng and the North West Province. The CHBH Respiratory Unit database from January 
2006 to December 2009 was reviewed.  An Excel (Microsoft Corporation, Bellevue, WA) 
database was compiled from discharge summaries and case notes of patients referred to the 
Respiratory Unit.   Permission to use the database was obtained from the database manager 
and permission to conduct this review was obtained by the Human Research Ethics 
committee of the University of the Witwatersrand. 
Patients meeting at least one of the established criteria of empyema; a) aspiration of pus from 
the pleural space, b) pleural fluid pH <7.2 or  pleural fluid glucose <3.4 mmol/l  or c) positive 
microbial stain and/or culture, 
1, 2 
were included.  Of the 250 records reviewed, 78 patients 
were excluded (fig 1).  The 29 patients excluded for chronic/unresolved empyema were 
patients that had been previously admitted for primary empyema, prior to the start date of the 
study, and had returned with complications during the study period.  We felt that inclusion of 
these patients would create bias.   
Patients were divided into aetiological groups based upon initial pleural fluid results: [1] 
proven tuberculosis (TB), [2] clinical TB, [3] dual (tuberculosis and bacterial infection), [4] 
bacterial, [5] non-tuberculous mycobacteria (NTM) and [5] unknown.  For proven TB either 
pleural fluid or sputum samples demonstrated Acid-Fast Bacilli (AFB) on microscopy and/or 
cultured Mycobacterium tuberculosis or pleural biopsy demonstrated histological features of 
tuberculous infection.  Patients with radiological features of TB, those in whom clinical 
suspicion of TB existed or responded to a trial of anti-tuberculous therapy were classified as 
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clinical TB.  Patients diagnosed with proven TB who also cultured a bacterial organism in 
their pleural fluid were classified as dual.  Patients with bacterial infections were subdivided 
into Gram-positive, Gram-negative and polymicrobial infections.  Patients in whom pleural 
fluid analysis or histology failed to identify a microbiological aetiology were classified as 
unknown. 
Outcomes were defined as: [1] resolution of empyema via closed tube thoracostomy in ≤14 
days, [2] resolution of empyema via closed tube thoracostomy but requiring insertion of 
multiple tubes or prolonged drainage (>14 days), [3] long-term open tube thoracostomy, [4]  
cardiothoracic intervention and [5] death.  Length of stay was compared among each group. 
Complications were defined as:  [1] wound sepsis at tube thoracostomy site and [2] secondary 
infection of the pleural space. 
Statistical analysis was performed using STATA 10 software (StataCorp LP, College Station, 
Texas).  Univariate analyses were performed in each of the groups against known risk factors 
for empyema; age, smoking, ethanol abuse and male sex.   Association between categorical 
variables were tested using Fisher’s exact test, odds ratios and 95% confidence intervals were 
calculated.  Continuous variables with parametric distributions were tested with the student’s 
t-test, those with nonparametric distributions with the Wilcoxon Rank Sum test.  Where 
significant risk factors were identified between groups, they were analysed using multivariate 
regression analyses.  Significance was considered as a P value of <0.05. 
 
RESULTS 
In total 172 patients were included, mean age was 39 (14-78).  The study group comprised 
110 (64%) males.  Using all cause admissions to the medical wards during the study period, it 
was found that males were at greater risk of developing empyema (p <0.0001, OR 2.40, 95% 
CI 2.00-2.88).  HIV infection was present in 125 (73%) patients.    (fig 2.) 
With regards the reported risk factors for the development of empyema, statistical differences 
were found among the HIV infected and non-infected groups for age (p = 0.0003) and sex    
(p = 0.05).  In HIV infected patients stratified according to CD4 cell count, ethanol abuse was 
found to be significant (p = 0.04).  No differences in risk factors were found in HIV infected 
patients stratified according to antiretroviral usage.  
Microbiological aetiologies were as follows; 34 (19.8%) patients had proven TB, 34 (19.8%) 
had clinical TB, 8 (4.7%) had dual infections, 55 (32%) had bacterial infections, 1 (0.6%) had 
NTM infection, and in 40 (23.3%), no microbiological aetiology was identified.  One patient 
cultured both Streptococcus pneumoniae and NTM and was classified as bacterial. We report 
5 cases of Salmonella non-typhi empyema, all five patients were HIV infected; four had CD4 
counts <100 cells/mm
3
, the fifth was on antiretroviral therapy with a CD4 count of 118 
cells/mm
3
.  Pleural fluid cultured Salmonella spp. in all five, in one Salmonella spp. was also 
cultured on sputum (Table 1). 
With regards aetiology; HIV non-infected patients more often had no identifiable 
microbiological aetiology identified (p < 0.005, OR 0.18, CI 0.08-0.40) whereas HIV 
infected patients with lower CD4 cell counts had a significantly greater likelihood of being 
diagnosed with clinical TB (p = 0.02, OR 2.98, CI 1.22-7.3) and showed a trend towards 
having a greater incidence of infections caused by Gram-negative organisms (OR 10.6).  
Antiretroviral therapy did not alter the aetiology of empyema.      
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Tube thoracostomas were inserted in the general medical wards in all but 11 (6.4%) patients; 
6 (3.5%) were transferred to cardiothoracic surgeons as their pleural collections were not 
amenable to tube thoracostomy, 3 (1.8%) had very small collections which were treated 
medically and 2 (1.2%) refused further hospital treatment.   
Following closed tube thoracostomy; 16 (10%) patients had complete resolution of empyema 
within 14 days, 34 (20.4%) had resolution with prolonged drainage or multiple tubes.  
Following 14 days of closed tube thoracostomy, 47 (28.1%) were discharged home with an 
open tube thoracostoma; 14 (29.8%) of these following basal tube insertion by cardiothoracic 
surgeons.  Thirty eight (22.8%) patients underwent definitive cardiothoracic surgery; 35 had 
pleural toilette and basal tube insertion with subsequent resolution, 1 had a decortication, and 
2 required thoracostomy.  Prior to resolution of empyema, 14 (8.3%) patients refused further 
treatment and discharged themselves from hospital.   
Of the patients converted to open tube thoracostomy; 6 (12.8%) were followed up by 
cardiothoracic services, 11 (23.4%) had resolution of empyema, 23 (48.9%) defaulted follow 
up, 5 (10.6%) were transferred to cardiothoracic surgeons for a definitive procedure; toilette, 
decortication, thoracostomy or thoracoplasty and 2 (4.3%) demised due to ongoing pleural 
sepsis.  
Overall length of stay was a median of 29 days (3-118 days).  No differences were found with 
regards to length of stay between HIV infected and non-infected patients or between those 
stratified according to CD4 cell count.  Patients on antiretroviral therapy had significantly 
shorter lengths of stay. 
Patients were evaluated for development of complications; 4 (2.4%) developed wound sepsis 
at tube thoracostomy site and 26 (15.6%) developed secondary infection of their pleural 
space.  Mortality in this series was 12.8% (22/172).  
Regarding outcomes and complications; HIV infected patients on antiretrovirals are more 
likely to be offered definitive cardiothoracic intervention.  Length of stay was shorter and, 
though not statistically significant, there were no mortalities amongst patients on 
antiretroviral therapy.  No other differences were found between the various groups (Table 
2). 
 
 DISCUSSION 
Empyema thoracis remains an important problem in South Africa.  Majority of empyemas 
(>50%) are as a result of direct extension of a pulmonary parenchymal infection into the 
pleural space.
1, 3     
Empyema in HIV infected patients is uncommon in developed countries 
despite the increased risk HIV infection confers to the development of respiratory 
infections.
8, 9
  In this series, at an ecological level there appears to be a strong association 
between HIV infection and the development of empyema with a disproportionate number of 
patients with empyema being HIV infected. 
The microbiology of empyema is vast.  Common pathogens include S. pneumoniae, 
Staphylococcus aureus, Streptococcus anginosus, Streptococcus pyogenes, Prevotella spp. 
and M. tuberculosis.
3
   Since the availability of antibiotics the bacteriology has changed; S. 
pneumonia and S. pyogenes infections occur less, and S. aureus and enteric Gram-negative 
organisms occur more frequently.
10, 11
   Infections caused by Gram-negative organisms occur 
more frequently in HIV infected patients
8
 and a trend which was found in our series.
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Infection with non-typhoidal salmonella is well described in patients with advanced HIV 
infection,
12
 bacteraemia occurs frequently however pleuropulmonary complications are rare, 
with empyema usually occurring in the setting of CD4 counts <100 cells/mm
3
.
13, 14
    The 
incidence of non-typhoidal salmonella reported in our series suggests that non-typhoidal 
salmonella should be considered potential aetiological organisms in HIV infected patients 
with low CD4 cell counts.  The identification of Pseudomonas aeruginosa and Acinetobacter 
baumannii as causes of empyema is worrying and may reflect the increased contact HIV 
infected patients have with health facilities.   There appears to be a resurgence of important 
pathogens from the pre-antibiotic era in the presence of the HIV pandemic.
 
Tuberculous empyema has been reported at frequencies of 3-6% in developed countries,
7, 8, 15
 
however in developing countries TB accounts for up to 35% of cases.
4
  In Southern Africa, 
majority of patients with tuberculous empyema are HIV infected.
16
    Rates of tuberculous 
empyema are higher in our series than those stated in developed countries; when combining 
the patients with proven and clinical TB, 44.2% of empyemas were attributed to tuberculous 
infection.  HIV infected patients tend to be given the diagnosis of clinical TB when no 
microbiological aetiology is found despite extensive investigation, we attribute this to 
clinician bias in a community where rates of HIV and TB co-infection are high.  Dual 
infections were only found in patients with HIV infection and occurred over a range of CD4 
counts (39-382 cells/mm
3
).  
Pleural involvement is unusual with NTM; pleural thickening adjacent to pulmonary 
parenchymal infection is described, pleural effusions if present are very small.
17, 18
  Empyema 
is rare with only one report of a clearly documented empyema due to NTM in a patient with 
advanced acquired immunodeficiency syndrome.
19
  NTM were cultured in two patients 
(Mycobacterium  avium-intracellulare in one, failed identification of species in the other due 
to contamination), both were HIV infected with advanced disease; CD4 counts of 7 and 25 
cells/mm
3
 and neither was on antiretroviral therapy.  
Despite thorough investigation no identifiable microbiological aetiology for empyema was 
identified in 23.3%; patients may have been treated with antibiotics prior to admission or 
specimens for anaerobic cultures may not have been optimally processed thus underreporting 
anaerobic infections.  Anaerobic bacteria remain important pathogens in adults.
20
  Rapid 
transfer in oxygen-free media to the laboratory and adequate anaerobic culture techniques are 
vital to increase diagnostic sensitivity.
10
   
The treatment of empyema depends upon the pathophysiological stage in which the patient 
presents.  Empyemas in the exudative stage, may be successfully drained via closed tube 
thoracostomy.
7, 21, 22
  Empyemas in the fibrinopurulent stage often require more aggressive 
drainage procedures or video-assisted thoracoscopy.
21, 22, 23
  There is contradictory evidence 
on the use of intrapleural fibrinolytics; they may be used as an adjunct to closed tube 
thoracostomy however do not reduce mortality or the need for surgery.
24, 25  
Thoracoscopic 
drainage procedures are popular; less post operative pain, lower costs, shorter hospital stays 
and better cosmetic results.
24, 26
  Optimal timing is important as high failure rates have been 
reported in cases with advanced empyema.
27, 28
  Empyema in the organisational stage is best 
managed via open surgery; decortication, thoracostomy or thoracoplasty to manage extensive 
pleural peel or control the underlying inflammatory process.
7, 21, 23
  Decortication remains the 
modality of choice for treating advanced empyema, thoracoplasty and thoracostoma are 
reserved for debilitated patients who cannot tolerate aggressive surgery or those in whom 
decortication has failed.
21, 29
  The success rate of closed tube thoracostomy for advanced or 
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loculated empyema is low 
7, 21
 and the mortality of empyema treated by closed tube 
thoracostomy is high, 11-24%.
21, 29
 
In our series 30.4% of patients were successfully treated via closed tube thoracostomy, 
however many required multiple tubes or prolonged drainage.  Cardiothoracic intervention as 
a primary therapeutic measure was offered to only 6 (3.5%) patients, surgery was offered to 
another 46 (26.7%).  Of the 52 patients who underwent surgery, 38 (22.1%) had definitive 
surgery, 14 (8.1%) were discharged home with open tube thoracostomas and 2 (3.9%) 
demised.  Development of local complications in 15 (28.9%) patients or the necessity for 
multiple tube insertions in 15 (28.9%) appeared to be the criteria for surgery.  Surgery was 
more readily offered to patients on antiretroviral therapy. 
Long-term open tube thoracostomy via a tube thoracostomy cut short and the placement of a 
colostomy bag over the cut end of the tube is a technique (which we could not find described 
in the literature) used due to limited cardiothoracic resources available to us. The empyema 
space is allowed to drain freely and with regular withdrawal of the tube, the pleural space 
eventually obliterates.  Of the 47 patients discharged with open tube thoracostomas, we were 
able to assess the outcomes in 38%.  Of these, 11 (61%) patients had ultimate resolution, thus 
open tube thoracostomy may be a viable alternate treatment option in settings with limited 
cardiothoracic services.  The high rate of patients lost to follow up doesn’t allow for accurate 
assessment, however it is an intriguing alternative treatment and further prospective studies 
should be undertaken to assess this method further.   
A significant proportion of patients refused hospital treatment; they had either required 
multiple tube insertion or waited for long periods of time for cardiothoracic intervention.  
Mortality in this series is in line with that of current literature, but may be underreported 
considering many patients refused hospital treatment or were lost to follow up.   
Although this is a very large retrospective case series of empyema in HIV infected patients, 
this study is limited by the sample size of the subgroups and may not have had sufficient 
power to show statistical significance between the various groups.  The fact that 
cardiothoracic surgery was offered largely only to patients on antiretroviral therapy is a 
further limitation as we were only able to assess whether patients underwent surgery as 
opposed to the need for cardiothoracic intervention.  Only subjects referred to the respiratory 
unit were analysed and subjects with uncomplicated courses may have been excluded.   
 
 CONCLUSION 
This is the largest series of empyema in HIV infected patients.  It suggests that HIV infection 
is strongly associated with the  development of empyema.  We were unable to show that HIV 
alters the aetiology of empyema however a trend towards infection with enteric Gram-
negative organisms in particular Salmonella spp. was found and a further case of NTM 
empyema is described.  Clinical outcomes were similar in HIV infected and non-infected 
patients.  Bias towards patients on antiretroviral therapy with regards to surgical intervention 
exists; and may translate to shorter length of stay or even reduced mortality. 
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250 Records Reviewed 
Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Flowchart summarising patient inclusion. 
 
 
 
 
 
 
 
 
125 HIV Infected 
47 HIV non-infected 172 Patients included 
78 Patients Excluded:                                 
- 29 Unresolved / Chronic empyema                            
- 19 Insufficient Data                                                                          
 - 7 HIV status unknown                                          
 - 12 No smoking or ethanol history 
- 13 Iatrogenic empyema                                         
- 8 Sub-diaphragmatic pathology                    
- 3 Malignant effusions                                   
- 2 Penetrating chest trauma                           
- 1 Not biochemically empyema                     
- 1 Post thoracic surgery                                      
- 2 Chest wall abscess, not empyema 
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Figure 2 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Flowchart summarising HIV infected patients’ characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
125 HIV Infected (73%) 
Median CD4 cell count 128 cells/mm
3
 (1-885 cells/mm
3
, IQR 62-219 cells/mm
3
) 
88 CD4 count <200 cells/mm3 
(70.4%) 
37 CD4 count ≥ 200 cells/mm3 
(29.6%) 
14 on ART 
(11.2%) 
5 on ART 
(4%) 
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Table 1 
Microbiological aetiologies by HIV Status 
 
 HIV Positive (n=125) HIV Negative (n=47) 
   
* Proven Tuberculosis:  34 (27.2%) 8 (17%) 
 Pleural Fluid Microscopy AFB positive 7 (20.6%) 0 
 Pleural Fluid culture MTB positive  18 (53.0%) 1 (12.5%) 
 Sputum Microscopy AFB positive 12 (35.5%) 4 (50%) 
 Sputum Culture MTB positive 9 (26.5%) 2 (25%) 
Blood Culture MTB positive  3 (8.8%) 0 
 Pleural Biopsy consistent with tuberculosis 2 (5.9%) 2 (25%) 
   
Clinical Tuberculosis: 27 (21.6%) 7 (14.9%) 
   
* Bacterial Infection: 53 (42.4%) 10 (21.3%) 
 S. pneumoniae 22 (41.5%) 3 (30%) 
S. anginosus (formerly S. milleri) 5 (9.4%) 5 (50%) 
K. pneumonia 5 (9.4%) 1 (10%) 
 Salmonella spp. 5 (9.4%) 0 
S. aureus 3 (5.7%) 0 
Peptostreptococcus spp. 3 (5.7%) 1 (10%) 
 E. coli 3 (5.7%) 0 
Prevotella spp. 2 (3.8%) 3 (30%) 
Nocardia spp. 2 (3.8%) 0 
H. influenza 2 (3.8%) 0 
P. mirabilis 2 (3.8%) 0 
 P. aeruginosa 2 (3.8%) 0 
E. faecium 1 (1.9%) 0 
 E. faecalis 1 (1.9%) 0 
 S. viridans 1 (1.9%) 0 
S. pyogenes 1 (1.9%) 0 
A. baumannii 1 (1.9%) 0 
 Streptococcus Group F 1 (1.9%) 0 
Streptococcus Group C 0 1 (10%) 
   
Non-tuberculous mycobacteria: 1 (0.8%) 0 
 Mycobacterium avium-intracellulare complex 1 (0.8%) 0 
   
Unknown: 18 (14.4%) 22 (46.8%) 
   
MTB = Mycobacterium tuberculosis 
* Includes those with dual infection. 
Proof of MTB often obtained by more than one method. 
Polymicrobial infection in 13 patients.
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Table 2 
Differences in outcomes and complications of empyema 
 
   P OR (95%) 
     
† HIV infected versus non infected patients: HIV Negative (n=47) HIV Positive (n=125)   
 § Length of stay  27 (4 – 94) 29 (3 – 118) 0.65  
 Resolution Simple 4 12 0.78 0.83 (0.24 – 2.88) 
 Resolution Complicated 8 26 0.50 1.38 (0.54 – 3.52) 
 Long term open tube thoracostomy 13 32 0.80 0.90 (0.41 – 1.99) 
 Definitive surgical intervention  12 26 0.42 1.13 (0.31 – 1.62) 
 Death 6 16 0.80 0.78 (0.40 – 3.40) 
 Wound sepsis at tube thoracostomy site 1 3 0.88 1.21 (0.10 – 14.72) 
 Secondary infection of pleural space 5 21 0.17 2.19 (0.71 – 6.71) 
     
‡ CD4 <200 versus ≥200 cells/mm3: CD4 < 200 (n=88) CD4 ≥ 200 (n=37)   
 § Length of stay  29 (4 – 118) 31 (3 – 88) 0.73  
 Resolution Simple 8 4 0.84 1.14 (0.32 – 4.09) 
 Resolution Complicated 18 8 0.82 1.11 (0.43 – 2.90) 
 Long term open tube thoracostomy 23 9 0.98 0.99 (0.40 – 2.45) 
 Definitive surgical intervention  18 8 0.89 1.07 (0.42 – 2.75) 
 Death 14 2 0.10 0.27 (0.06 – 1.30) 
 Wound sepsis at tube thoracostomy site 3 0 * * 
 Secondary infection of pleural space 15 6 0.82 1.00 (0.99 – 1.00) 
     
¤ ART versus no ART: ART (n=19) No ART (n=106)   
 § Length of stay  37 (19 – 71) 27 (3 – 118) 0.05  
 Resolution Simple 1 11 0.69 0.47 (0.01 – 3.60) 
 Resolution Complicated 4 22 1.00 0.98 (0.22 – 3.52) 
 Long term open tube thoracostomy 5 27 1.00 1.01 (0.26 – 3.32) 
 Definitive surgical intervention  8 18 0.03 3.43 (1.03 – 10.90) 
 Death 0 16 * * 
 Wound sepsis at tube thoracostomy site 1 2 0.39 2.89 (0.05 – 57.56) 
 Secondary infection of pleural space 2 19 0.74 0.54 (0.06 – 2.61) 
     
ART = Antiretroviral therapy                     † Adjusted in logistic regression analysis for age and sex.             
‡ Adjusted in logistic regression analysis for ethanol abuse, CD4 cell count only done for HIV.              ¤ Univariate analysis using 2-tailed Fisher’s exact test                   
* P value, odds ratios and 95% confidence intervals were not calculated in groups which included a zero.              § Length of stay adjusted in linear regression analysis. 
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Appendix H 
Comparison of empyema thoracis in HIV infected and non-infected patients with regards to 
aetiology and outcome. 
 
Empyema thoracis in HIV infection.                                                                                                                                                                                    
 
ABSTRACT 
Background:  Empyema thoracis remains a problem in developing countries.  Human 
Immunodeficiency Virus (HIV) is a risk factor for the development of empyema.  There is a 
clinical impression that HIV infected patients with empyema have worse outcomes.  This 
study was conducted to assess whether HIV infection affected aetiology or outcomes of 
patients with empyema. 
Methods:  A retrospective review was conducted of patients, meeting established criteria for 
the diagnosis of empyema, admitted to Chris Hani Baragwanath Hospital (CHBH) from 
January 2006 to December 2009.  HIV infected and non-infected patients were evaluated for 
differences in aetiology and outcomes including; length of stay,  surgical intervention and 
local complications of closed tube thoracostomy.  A sub analysis of HIV infected patients 
stratified according to CD4 cell count and antiretroviral use was also performed. 
Results:   One hundred and seventy two patients were included, 125 (73%) were HIV 
infected and 47 (27%) were HIV non-infected.  HIV infected patients with lower CD4 cell 
counts were more likely to be diagnosed with clinical tuberculosis.  The aetiology of 
empyema was more commonly not determined in HIV non-infected patients.  HIV infected 
patients on antiretrovirals were more likely to have thoracic surgery and had shorter hospital 
stays than those not on antiretrovirals. 
Conclusions:  This study failed to demonstrate any significant differences in aetiology 
among HIV infected versus non-infected patients with empyema.  There was a trend towards 
more Gram-negative infections in the HIV infected group.  Antiretroviral use was associated 
with improved outcomes with regards to cardiothoracic intervention and length of stay.  
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INTRODUCTION 
Empyema thoracis; the presence of pus in the pleural space,
1, 2, 3 
remains a problem in 
developing countries,
4
 its course is often prolonged and frequently requires surgical drainage.  
HIV infection is a risk factor for empyema
1
 and complicates pneumonia more frequently in 
HIV infected patients.
5
   Reported risk factors for the development of empyema include 
serum albumin <30 g/dl, intravenous drug use, ethanol abuse, younger age, male sex and 
current smoking. 
6 
In our experience, majority of patients with empyema are HIV infected and present with late 
stages of empyema.  Despite expected low success rates of closed tube thoracostomy in the 
treatment of late empyema
7
 it remains first-line therapy at our hospital as cardiothoracic 
services are limited and many patients are critically ill and unable to tolerate aggressive 
surgical procedures.   
There is an impression that HIV infected patients do worse clinically.  Limited literature 
exists to support this, some reports claim patients with CD4 counts <200 cells/mm
3 
have 
higher complication rates and a poorer prognosis.
5
 
This study compares microbiological aetiology, outcomes including; length of stay, whether 
surgical intervention was offered and local complications of tube thoracostomy, in patients 
with empyema according to HIV status.  A secondary objective is to compare aetiology and 
outcomes in patients with HIV infection stratified according to CD4 cell count (≥200 
cells/mm
3
 or <200 cells/mm
3
) and antiretroviral usage. 
 
METHODS 
CHBH is a large academic hospital in Soweto Johannesburg, with 847 medical beds.  It is the 
only in-patient facility for the greater Soweto area and serves as a referral centre for Southern 
Gauteng and the North West Province. The CHBH Respiratory Unit database from January 
2006 to December 2009 was reviewed.  An Excel (Microsoft Corporation, Bellevue, WA) 
database was compiled from discharge summaries and case notes of patients referred to the 
Respiratory Unit.   Permission to use the database was obtained from the database manager 
and permission to conduct this review was obtained by the Human Research Ethics 
committee of the University of the Witwatersrand. 
Patients meeting at least one of the established criteria of empyema; a) aspiration of pus from 
the pleural space, b) pleural fluid pH <7.2 or pleural fluid glucose <3.4 mmol/l, or c) positive 
microbial stain and/or culture, 
1, 2 
were included.   
Patients were divided into aetiological groups based upon initial pleural fluid results: [1] 
proven tuberculosis (TB), [2] clinical TB, [3] dual (tuberculosis and bacterial infection), [4] 
bacterial, [5] non-tuberculous mycobacteria (NTM) and [5] unknown.  For proven TB either 
pleural fluid or sputum samples demonstrated Acid-Fast Bacilli (AFB) on microscopy and/or 
cultured Mycobacterium tuberculosis, or pleural biopsy demonstrated histological features of 
tuberculous infection.  Patients with radiological features of TB, those in whom clinical 
suspicion of TB existed or responded to a trial of anti-tuberculous therapy were classified as 
clinical TB.  Patients diagnosed with proven TB who also cultured a bacterial organism in 
their pleural fluid were classified as dual.  Patients with bacterial infections were subdivided 
into Gram-positive, Gram-negative and polymicrobial infections.  Patients in whom pleural 
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fluid analysis or histology failed to identify a microbiological aetiology were classified as 
unknown. 
Outcomes were defined as: [1] resolution of empyema via closed tube thoracostomy in ≤14 
days, [2] resolution of empyema via closed tube thoracostomy but requiring insertion of 
multiple tubes or prolonged drainage (>14 days), [3] long-term open tube thoracostomy, [4]  
cardiothoracic intervention and [5] death.  Length of stay was compared among each group. 
Complications were defined as:  [1] wound sepsis at tube thoracostomy site and [2] secondary 
infection of the pleural space. 
Statistical analysis was performed using STATA 10 software (StataCorp LP, College Station, 
Texas).  Univariate analyses were performed in each of the groups against known risk factors 
for empyema; age, smoking, ethanol abuse and male sex.   Association between categorical 
variables were tested using Fisher’s exact test, odds ratios and 95% confidence intervals were 
calculated.  Continuous variables with parametric distributions were tested with the student’s 
t-test, those with nonparametric distributions with the Wilcoxon Rank Sum test.  Where 
significant risk factors were identified between groups, they were analysed using multivariate 
regression analyses.  Significance was considered as a P value of <0.05. 
 
RESULTS 
Two hundred and fifty records were reviewed, 78 patients were excluded (fig 1).  The 29 
patients excluded for chronic/unresolved empyema were patients that had been previously 
admitted for primary empyema, prior to the start date of the study, and had returned with 
complications during the study period.  We felt that inclusion of these patients would create 
bias.   
In total 172 patients were included, mean age was 39 (14-78).  The study group comprised 
110 (64%) males.  Using all cause admissions to the medical wards during the study period, it 
was found that males were at greater risk of developing empyema (p <0.0001, OR 2.40, 95% 
CI 2.00-2.88).  HIV infection was present in 125 (73%) patients (fig 2). 
With regards the reported risk factors for the development of empyema, statistical differences 
were found among the HIV infected and non-infected groups for age (p = 0.0003) and sex    
(p = 0.05).  In HIV infected patients stratified according to CD4 cell count, ethanol abuse was 
found to be significant (p = 0.04).  No differences in risk factors were found in HIV infected 
patients stratified according to antiretroviral usage.  
Microbiological aetiologies were as follows; 34 (19.8%) patients had proven TB, 34 (19.8%) 
had clinical TB, 8 (4.7%) had dual infections, 55 (32%) had bacterial infections, 1 (0.6%) had 
NTM infection, and in 40 (23.3%), no microbiological aetiology was identified.  One patient 
cultured both Streptococcus pneumoniae and NTM and was classified as bacterial. We report 
5 cases of Salmonella non-typhi empyema, all five patients were HIV infected; four had CD4 
counts <100 cells/mm
3
, the fifth was on antiretroviral therapy with a CD4 count of 118 
cells/mm
3
.  Pleural fluid cultured Salmonella spp. in all five, in one Salmonella spp. was also 
cultured on sputum (Table 1). 
With regards aetiology; HIV non-infected patients more often had no identifiable 
microbiological aetiology identified (p < 0.005, OR 0.18, CI 0.08-0.40) whereas HIV 
infected patients with lower CD4 cell counts had a significantly greater likelihood of being 
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diagnosed with clinical TB (p = 0.02, OR 2.98, CI 1.22-7.3) and showed a trend towards 
having a greater incidence of infections caused by Gram-negative organisms (OR 10.6).  
Antiretroviral therapy did not alter the aetiology of empyema.      
Tube thoracostomas were inserted in the general medical wards in all but 11 (6.4%) patients; 
6 (3.5%) were transferred to cardiothoracic surgeons as their pleural collections were not 
amenable to tube thoracostomy, 3 (1.8%) had very small collections which were treated 
medically and 2 (1.2%) refused further hospital treatment.   
Following closed tube thoracostomy; 16 (10%) patients had complete resolution of empyema 
within 14 days, 34 (20.4%) had resolution with prolonged drainage or multiple tubes.  
Following 14 days of closed tube thoracostomy, 47 (28.1%) were discharged home with an 
open tube thoracostoma; 14 (29.8%) of these following basal tube insertion by cardiothoracic 
surgeons.  Thirty eight (22.8%) patients underwent cardiothoracic surgery; 35 had pleural 
toilette and basal tube insertion with subsequent resolution, 1 had a decortication, and 2 
required thoracostomy.  Prior to resolution of empyema, a further 12 (7%) patients refused 
further treatment and discharged themselves from hospital.   
Of the patients converted to open tube thoracostomy; 6 (12.8%) were followed up by 
cardiothoracic services, 11 (23.4%) had resolution of empyema, 23 (48.9%) defaulted follow 
up, 5 (10.6%) were transferred to cardiothoracic surgeons for a definitive procedure; toilette, 
decortication, thoracostomy or thoracoplasty and 2 (4.3%) demised due to ongoing pleural 
sepsis.  
Overall length of stay was a median of 29 days (3-118 days).  No differences were found with 
regards to length of stay between HIV infected and non-infected patients or between those 
stratified according to CD4 cell count.  Patients on antiretroviral therapy had significantly 
shorter lengths of stay. 
Patients were evaluated for development of complications; 4 (2.4%) developed wound sepsis 
at tube thoracostomy site and 26 (15.6%) developed secondary infection of their pleural 
space.  Mortality in this series was 12.8% (22/172), 20 patients died in the medical wards and 
2 died post surgical intervention.  
Regarding outcomes and complications; HIV infected patients on antiretrovirals are more 
likely to be offered definitive cardiothoracic intervention.  Length of stay was shorter and, 
though not statistically significant, there were no mortalities amongst patients on 
antiretroviral therapy.  No other differences were found between the various groups (Table 
2). 
 
DISCUSSION 
Empyema thoracis remains an important problem in South Africa.  Majority of empyemas 
(>50%) are as a result of direct extension of a pulmonary parenchymal infection into the 
pleural space.
1, 3     
Empyema in HIV infected patients is uncommon in developed countries 
despite the increased risk HIV infection confers to the development of respiratory 
infections.
8, 9
  In this series, at an ecological level there appears to be a strong association 
between HIV infection and the development of empyema with a disproportionate number of 
patients with empyema being HIV infected. 
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The microbiology of empyema is vast.  Common pathogens include S. pneumoniae, 
Staphylococcus aureus, Streptococcus anginosus, Streptococcus pyogenes, Prevotella spp. 
and M. tuberculosis.
3
   Since the availability of antibiotics the bacteriology has changed; S. 
pneumonia and S. pyogenes infections occur less, and S. aureus and enteric Gram-negative 
organisms occur more frequently.
10, 11
   Infections caused by Gram-negative organisms occur 
more frequently in HIV infected patients
8
 and a trend which was found in our series.
 
  
Infection with non-typhoidal salmonella is well described in patients with advanced HIV 
infection,
12
 bacteraemia occurs frequently however pleuropulmonary complications are rare, 
with empyema usually occurring in the setting of CD4 counts <100 cells/mm
3
.
13, 14
    The 
incidence of non-typhoidal salmonella reported in our series suggests that non-typhoidal 
salmonella should be considered potential aetiological organisms in HIV infected patients 
with low CD4 cell counts.  The identification of Pseudomonas aeruginosa and Acinetobacter 
baumannii as causes of empyema is worrying and may reflect the increased contact HIV 
infected patients have with health facilities.   There appears to be a resurgence of important 
pathogens from the pre-antibiotic era in the presence of the HIV pandemic.
 
Tuberculous empyema has been reported at frequencies of 3-6% in developed countries,
7, 8, 15
 
however in developing countries TB accounts for up to 35% of cases.
4
  In Southern Africa, 
majority of patients with tuberculous empyema are HIV infected.
16
    Rates of tuberculous 
empyema are higher in our series than those stated in developed countries; when combining 
the patients with proven and clinical TB, 44.2% of empyemas were attributed to tuberculous 
infection.  HIV infected patients tend to be given the diagnosis of clinical TB when no 
microbiological aetiology is found despite extensive investigation, we attribute this to 
clinician bias in a community where rates of HIV and TB co-infection are high.  Dual 
infections were only found in patients with HIV infection and occurred over a range of CD4 
counts (39-382 cells/mm
3
).  
Pleural involvement is unusual with NTM; pleural thickening adjacent to pulmonary 
parenchymal infection is described, pleural effusions if present are very small.
17, 18
  Empyema 
is rare with only one report of a clearly documented empyema due to NTM in a patient with 
advanced acquired immunodeficiency syndrome.
19
  NTM were cultured in two patients 
(Mycobacterium  avium-intracellulare in one, failed identification of species in the other due 
to contamination), both were HIV infected with advanced disease; CD4 counts of 7 and 25 
cells/mm
3
 and neither was on antiretroviral therapy.  
Despite thorough investigation no identifiable microbiological aetiology for empyema was 
identified in 23.3%; patients may have been treated with antibiotics prior to admission or 
specimens for anaerobic cultures may not have been optimally processed thus underreporting 
anaerobic infections.  Anaerobic bacteria remain important pathogens in adults.
20
  Rapid 
transfer in oxygen-free media to the laboratory and adequate anaerobic culture techniques are 
vital to increase diagnostic sensitivity.
10
   
The treatment of empyema depends upon the pathophysiological stage in which the patient 
presents.  Empyemas in the exudative stage, may be successfully drained via closed tube 
thoracostomy.
7, 21, 22
  Empyemas in the fibrinopurulent stage often require more aggressive 
drainage procedures or video-assisted thoracoscopy.
21, 22, 23
  There is contradictory evidence 
on the use of intrapleural fibrinolytics; they may be used as an adjunct to closed tube 
thoracostomy however do not reduce mortality or the need for surgery.
24, 25  
Thoracoscopic 
drainage procedures are popular; less post operative pain, lower costs, shorter hospital stays 
and better cosmetic results.
24, 26
  Optimal timing is important as high failure rates have been 
reported in cases with advanced empyema.
27, 28
  Empyema in the organisational stage is best 
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managed via open surgery; decortication, thoracostomy or thoracoplasty to manage extensive 
pleural peel or control the underlying inflammatory process.
7, 21, 23
  Decortication remains the 
modality of choice for treating advanced empyema, thoracoplasty and thoracostoma are 
reserved for debilitated patients who cannot tolerate aggressive surgery or those in whom 
decortication has failed.
21, 29
  The success rate of closed tube thoracostomy for advanced or 
loculated empyema is low 
7, 21
 and the mortality of empyema treated by closed tube 
thoracostomy is high, 11-24%.
21, 29
 
In our series 30.4% of patients were successfully treated via closed tube thoracostomy, 
however many required multiple tubes or prolonged drainage.  Cardiothoracic intervention as 
a primary therapeutic measure was offered to only 6 (3.5%) patients, surgery was offered to 
another 46 (26.7%).  Development of local complications in 15 (28.9%) patients or the 
necessity for multiple tube insertions in 15 (28.9%) appeared to be the criteria for surgery.  
Surgery was more readily offered to patients on antiretroviral therapy. 
Long-term open tube thoracostomy via a tube thoracostomy cut short and the placement of a 
colostomy bag over the cut end of the tube is a technique (which we could not find described 
in the literature) used due to limited cardiothoracic resources available to us. The empyema 
space is allowed to drain freely and with regular withdrawal of the tube, the pleural space 
eventually obliterates.  Of the 47 patients discharged with open tube thoracostomas, we were 
able to assess the outcomes in 38%.  Of these, 11 (61%) patients had ultimate resolution, thus 
open tube thoracostomy may be a viable alternate treatment option in settings with limited 
cardiothoracic services.  The high rate of patients lost to follow up doesn’t allow for accurate 
assessment, however it is an intriguing alternative treatment and further prospective studies 
should be undertaken to assess this method further.   
A significant proportion of patients refused hospital treatment; they had either required 
multiple tube insertion or waited for long periods of time for cardiothoracic intervention.  
Mortality in this series is in line with that of current literature, but may be underreported 
considering many patients refused hospital treatment or were lost to follow up.   
Although this is a very large retrospective case series of empyema in HIV infected patients, 
this study is limited by the sample size of the subgroups and may not have had sufficient 
power to show statistical significance between the various groups.  The fact that 
cardiothoracic surgery was offered largely only to patients on antiretroviral therapy is a 
further limitation as we were only able to assess whether patients underwent surgery as 
opposed to the need, as described in the literature, for cardiothoracic intervention.  Only 
subjects referred to the respiratory unit were analysed and subjects with uncomplicated 
courses may have been excluded.   
 
 CONCLUSION 
This is the largest series of empyema in HIV infected patients.  It suggests that HIV infection 
is strongly associated with the development of empyema.  We were unable to show that HIV 
alters the aetiology of empyema however a trend towards infection with enteric Gram-
negative organisms in particular Salmonella spp. was found and a further case of NTM 
empyema is described.  Clinical outcomes were similar in HIV infected and non-infected 
patients.  Bias towards patients on antiretroviral therapy with regards to surgical intervention 
exists; and may translate to shorter length of stay or even reduced mortality. 
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250 Records Reviewed 
Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Flowchart summarising patient inclusion. 
 
 
 
 
 
 
 
 
125 HIV Infected 
47 HIV non-infected 172 Patients included 
78 Patients Excluded:                                 
- 29 Unresolved / Chronic empyema                            
- 19 Insufficient Data                                                                          
 - 7 HIV status unknown                                          
 - 12 No smoking or ethanol history 
- 13 Iatrogenic empyema                                         
- 8 Sub-diaphragmatic pathology                    
- 3 Malignant effusions                                   
- 2 Penetrating chest trauma                           
- 1 Not biochemically empyema                     
- 1 Post thoracic surgery                                      
- 2 Chest wall abscess, not empyema 
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Figure 2 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Flowchart summarising HIV infected patients’ characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
125 HIV Infected (73%) 
Median CD4 cell count 128 cells/mm
3
 (1-885 cells/mm
3
, IQR 62-219 cells/mm
3
) 
88 CD4 count <200 cells/mm3 
(70.4%) 
37 CD4 count ≥ 200 cells/mm3 
(29.6%) 
14 on ART 
(11.2%) 
5 on ART 
(4%) 
 
57 
 
Table 1 
Microbiological aetiologies by HIV Status 
 
 HIV Positive (n=125) HIV Negative (n=47) 
   
* Proven Tuberculosis:  34 (27.2%) 8 (17%) 
 Pleural Fluid Microscopy AFB positive 7 (20.6%) 0 
 Pleural Fluid culture MTB positive  18 (53.0%) 1 (12.5%) 
 Sputum Microscopy AFB positive 12 (35.5%) 4 (50%) 
 Sputum Culture MTB positive 9 (26.5%) 2 (25%) 
Blood Culture MTB positive  3 (8.8%) 0 
 Pleural Biopsy consistent with tuberculosis 2 (5.9%) 2 (25%) 
   
Clinical Tuberculosis: 27 (21.6%) 7 (14.9%) 
   
* Bacterial Infection: 53 (42.4%) 10 (21.3%) 
 S. pneumoniae 22 (41.5%) 3 (30%) 
S. anginosus (formerly S. milleri) 5 (9.4%) 5 (50%) 
K. pneumonia 5 (9.4%) 1 (10%) 
 Salmonella spp. 5 (9.4%) 0 
S. aureus 3 (5.7%) 0 
Peptostreptococcus spp. 3 (5.7%) 1 (10%) 
 E. coli 3 (5.7%) 0 
Prevotella spp. 2 (3.8%) 3 (30%) 
Nocardia spp. 2 (3.8%) 0 
H. influenza 2 (3.8%) 0 
P. mirabilis 2 (3.8%) 0 
 P. aeruginosa 2 (3.8%) 0 
E. faecium 1 (1.9%) 0 
 E. faecalis 1 (1.9%) 0 
 S. viridans 1 (1.9%) 0 
S. pyogenes 1 (1.9%) 0 
A. baumannii 1 (1.9%) 0 
 Streptococcus Group F 1 (1.9%) 0 
Streptococcus Group C 0 1 (10%) 
   
Non-tuberculous mycobacteria: 1 (0.8%) 0 
 Mycobacterium avium-intracellulare complex 1 (0.8%) 0 
   
Unknown: 18 (14.4%) 22 (46.8%) 
   
MTB = Mycobacterium tuberculosis 
* Includes those with dual infection. 
Proof of MTB often obtained by more than one method. 
Polymicrobial infection in 13 patients.
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Table 2 
Differences in outcomes and complications of empyema 
 
   P OR (95%) 
     
† HIV infected versus non infected patients: HIV Negative (n=47) HIV Positive (n=125)   
 § Length of stay  27 (4 – 94) 29 (3 – 118) 0.65  
 Resolution Simple 4 12 0.78 0.83 (0.24 – 2.88) 
 Resolution Complicated 8 26 0.50 1.38 (0.54 – 3.52) 
 Long term open tube thoracostomy 13 32 0.80 0.90 (0.41 – 1.99) 
 Definitive surgical intervention  12 26 0.42 1.13 (0.31 – 1.62) 
 Death 6 16 0.80 0.78 (0.40 – 3.40) 
 Wound sepsis at tube thoracostomy site 1 3 0.88 1.21 (0.10 – 14.72) 
 Secondary infection of pleural space 5 21 0.17 2.19 (0.71 – 6.71) 
     
‡ CD4 <200 versus ≥200 cells/mm3: CD4 < 200 (n=88) CD4 ≥ 200 (n=37)   
 § Length of stay  29 (4 – 118) 31 (3 – 88) 0.73  
 Resolution Simple 8 4 0.84 1.14 (0.32 – 4.09) 
 Resolution Complicated 18 8 0.82 1.11 (0.43 – 2.90) 
 Long term open tube thoracostomy 23 9 0.98 0.99 (0.40 – 2.45) 
 Definitive surgical intervention  18 8 0.89 1.07 (0.42 – 2.75) 
 Death 14 2 0.10 0.27 (0.06 – 1.30) 
 Wound sepsis at tube thoracostomy site 3 0 * * 
 Secondary infection of pleural space 15 6 0.82 1.00 (0.99 – 1.00) 
     
¤ ART versus no ART: ART (n=19) No ART (n=106)   
 § Length of stay  37 (19 – 71) 27 (3 – 118) 0.05  
 Resolution Simple 1 11 0.69 0.47 (0.01 – 3.60) 
 Resolution Complicated 4 22 1.00 0.98 (0.22 – 3.52) 
 Long term open tube thoracostomy 5 27 1.00 1.01 (0.26 – 3.32) 
 Definitive surgical intervention  8 18 0.03 3.43 (1.03 – 10.90) 
 Death 0 16 * * 
 Wound sepsis at tube thoracostomy site 1 2 0.39 2.89 (0.05 – 57.56) 
 Secondary infection of pleural space 2 19 0.74 0.54 (0.06 – 2.61) 
     
ART = Antiretroviral therapy                     † Adjusted in logistic regression analysis for age and sex.             
‡ Adjusted in logistic regression analysis for ethanol abuse, CD4 cell count only done for HIV.              ¤ Univariate analysis using 2-tailed Fisher’s exact test                   
* P value, odds ratios and 95% confidence intervals were not calculated in groups which included a zero.              § Length of stay adjusted in linear regression analysis. 
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